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Abstract
Throughout the human history, the fight against bacterial infections had never stopped
but the remedies for bacterial infections were often insufficient and for many infectious diseases,
there was no treatment available. The revolution in antimicrobial infection therapy began with
the discovery of penicillin by Alexander Fleming in 1928. However, since the first introduction
of antibiotics, bacteria over time have evolved sophisticated resistant strains against almost all
the available antibiotics which cause selection pressure on the bacteria to evolve their genetic
makeup and develop resistance against such agents. Furthermore, bacteria can form surface
attached multicellular communities known as biofilms. Bacteria residing within biofilms are
protected by biofilms which renders the bacteria more difficult to eliminate because of the low
permeability of antibiotics through outer membranes. Combating such resistant bacteria is an
extremely difficult task if using antibiotics alone. Hence scientific community continuously
seeks new strategies to overpower these resistant bacteria.
The focus of the research work presented here is to develop a class of chimera ligands
that can bind to both pili and LecA protein of Pseudomonas aeruginosa to inhibit both swarming
motility and biofilm formation. The potential adjuvant agents of these chimera ligands that can
increase the effectiveness of antibiotics were demonstrated. In addition, the ability of our
adjuvant molecules to eliminate drug-tolerant bacteria and to reduce persisters, in combination
with antibiotics was demonstrated.
The binding property of chimera ligands was demonstrated by competitive fluorescence
polarization assay (LecA) and by adding a functional group to a ligand that can covalently attach
to the receptor protein only when the physical ligand-receptor binding takes place (Pili). In
addition, the effect of externally added pili on the swarming motility of Pseudomonas

aeruginosa was tested to support the mechanistic study of the pili as the receptor (or one of the
receptors) that will bind to rhamnolipids and our synthetic agents, and upon binding, causing the
bacterial activities.
For quantification of polysaccharides, two efficient detection and quantification methods
that make use of the negative charges of the alginate polymer and do not involve degradation of
the targeted polysaccharide were described. Both approaches provide efficient methods for
monitoring alginate production by mucoid Pseudomonas aeruginosa.
The effect of a class of synthetic analogs of rhamnolipids at controlling (promoting and
inhibiting) the biofilm formation activities of a non-rhamnolipid-producing strain – rhlA –
of Pseudomonas aeruginosa was demonstrated. The bioactive synthetic analogs of rhamnolipids
promote biofilm formation by rhlA mutant at low concentrations but inhibit the biofilm
formation at high concentrations. To explore the internal structures formed by the biofilms, the
wild-type biofilms formed with substantial topography (hills and valleys) when the sample is
under shaking conditions were observed by confocal microscope. Using this observation as a
comparison, the effect of synthetic analogs of rhamnolipids on promoting structured (porous)
biofilm of rhlA mutant, at intermediate concentrations between the low ones that promoted
biofilm formation and the high ones that inhibited biofilm formation was demonstrated. This
study suggests a potential chemical signaling approach to control multiple bacterial activities.
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Chapter 1 Introduction: The Need of Controlling Pathogen Activities of Bacteria

1.1 Bacteria activities – Biofilm, swarming, alginate production, and twitching motilities
– impact infectious diseases
1.1.1. Pseudomonas aeruginosa is related to multiple diseases
Pseudomonas aeruginosa (P. aeruginosa) is a gram-negative, rod-shaped
opportunistic pathogen associated with a wide range of diseases.1 Common victims of P.
aeruginosa infections are the patients with weakened immune systems and patients with
wounds from surgery or burn.2 The P. aeruginosa infection is especially prevalent among
the victims of cystic fibrosis (CF), which is a genetic disorder that disrupts the normal
function of epithelial cells where P. aeruginosa colonizes the lung and mutates to an
alginate overproducing mucoid phenotype.3-4 The alginate-containing matrix of the
mucoid strain is thought to allow the formation of protected microcolonies and provide
increased resistance to opsonization, phagocytosis, and destruction by antibiotics.5-6 In
addition, outer membrane permeability of P. aeruginosa is lower than that of Escherichia
coli (E. coli).7 P. aeruginosa is intrinsically resistant to many structurally unrelated
antimicrobial agents because of the low permeability of its outer membrane, the
constitutive expression of various efflux pumps with wide substrate specificity, and the
naturally occurring chromosomal AmpC beta-lactamase.8

1.1.2. The clinically relevant mucoid strain of P. aeruginosa
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Over time P. aeruginosa in the lungs of Cystic Fibrosis (CF) patients converts
into a mucoid strain which is known to overproduce and secrete the exopolysaccharide
alginate.3 Alginate production by CF strains is the major source of morbidity for CF
patients. This is mainly due to the ability of the bacteria to undergo genotypic and
phenotypic changes from the typical nonmucoid form to a mucoid phenotype.9 The
relationship between conversion to mucoidy and the establishment of chronic infection is
still not fully understood. Ever since its discovery in the 70s, the exact causes for this
conversion to mucoid has been elusive.10 Conflicting opinions have been on the
contribution from ligands on the airway cells of the patients.11-12 Kharazmi reported that
exposure of a P. aeruginosa to hydrogen peroxide will cause nonmucoid to mucoid
conversion.13 Yu and coworkers found that truncation of type IV pilin induces mucoidy in
certain nonmucoid strain.14 In vitro studies have also indicated that alginate reduces P.
aeruginosa uptake by rabbit neutrophils, guinea-pig alveolar macrophages, and murine
peritoneal macrophages, as well as reducing human neutrophil function.15-18 The most
common mutations responsible for the mucoid conversion are found in mucA, which
encodes an inner-membrane-associated anti-σ-factor.19-20 MucA normally limits the
expression of the algD operon, which encodes the enzymes required for alginate
synthesis.21-23 σ22, which is encoded by algU, regulates stress response and virulenceassociated genes and is involved, directly and indirectly, in the regulation of virulence
and motility in P. aeruginosa.24-26 This suggests the primary selective advantage of the
mucA mutations might be activation of the cellular envelope stress response, and the
overproduction of alginate might be a secondary consequence of the mutations. The
known or proposed pathogenic roles of alginate can be classified as the following

2

categories: 1) a direct physical barrier against phagocytic cells, 2) alginate production
may play a role in biofilm-related phenomena, including contribution to adhesion and
antibiotic resistance owing to the increased impermeability for antibiotics.3, 27-28 Parsek
and co-workers showed that the biofilm formed by mucoid strain was a thousand-fold
more resistant than the non-mucoid strain to the action of antibiotic Tobramycin.29
Hengzhuang and coworkers demonstrated that the treatment of biofilms formed by
mucoid strains required higher doses and longer treatment times with two antibiotics,
Colistin and Imipenem, as compared to the biofilms of nonmucoid strain.30 Singh and
coworkers did explore the use of Esomeprazole molecules to control the biofilms formed
by mucoid strain.31 In chapter 2, we will introduce a novel alginate quantification method
that offers better chemoselectivity and easier operations over a conventionally used
carbazole assay. We also focused on discovering synthetic molecules on inhibiting
alginate produced by a pathogenic strain of P. aeruginosa (mucoid phenotype) extracted
from cystic fibrosis patients.
1.1.3. Bacterial biofilms are a major source of infectious diseases and persistent
pathogens
Biofilm is any group of microorganisms in which cells stick to each other on a
surface.32 P. aeruginosa biofilms are difficult to eliminate because of the low
permeability of antibiotics through outer membranes of P. aeruginosa.33-34 Parsek and
his co-workers found that the biofilm formed by mucoid strain was 1000 times more
resistant than the non-mucoid strain to the action of antibiotics.7 About 80 % of bacterial
infections in humans are associated with biofilms.35 Bacteria residing inside the biofilms
are phenotypically different from those within the culture.36 Biofilm formation is
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commonly considered to occur in the following main stages.(See Figure 1.1) The first
step of biofilm formation is the reversible attachment of bacteria on the biotic or abiotic
surfaces which is governed by Van der Waals forces and at this stage bacteria can be
easily removed from the surface.37 In the second step, bacteria adhere irreversibly onto
the surface through its pili and flagella.8 In the third step, bacteria start communicating
with each other through quorum sensing. When a quorum is achieved, bacteria start
secreting polysaccharides to create a three-dimensional matrix. The fourth step in the
process is the formation of mature biofilms. Mature biofilm is usually a mushroomshaped structure consisting of different phenotypes as we move from cap to root of the
mushroom. The last step of biofilm formation is a dispersion of mature biofilm.
Dispersion is an important stage of the biofilm cycle as it allows bacteria to spread and
colonize new surfaces.38
The stimulation of biofilm production induced by sub-inhibitory concentrations of
antibiotics was observed in numerous human pathogens, such as Staphylococcus or
Pseudomonas species.39 Biofilms can directly challenge the treatment of infectious
diseases by greatly reducing the antibacterial efficacy of antibiotics.40-41 Within a biofilm,
bacteria face gradients of physical and chemical parameters, such as nutrients, oxygen,
pH.40 Thus, those bacteria living within biofilms are in distinct physiological states,
which increased their capacity to tolerate antibiotics. In addition, the physical barrier
created by the biofilm structure can hinder the diffusion of antibiotics.29, 33 Biofilm
formation, induced by sub-inhibitory concentrations of antibiotics targeting ribosomes,
such as aminoglycosides, phenicols or tetracyclines, was shown to involve cyclic-diGMP signaling both in P. aeruginosa and E. coli.42 In P. aeruginosa, biofilm induction
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requires the presence of an inner membrane protein, coded by the arr gene, containing an
EAL domain, which is commonly present in enzymes involved in the degradation of the
cyclic-di-GMP, thus aminoglycosides may modulate the level of this second messenger
by acting on the inner membrane protein.42

Figure 1.1 The five stages of biofilm development. Stage 1: Planktonic (free-floating)
bacteria adhere to the biomaterial surface. Stage 2: Cells aggregate, form microcolonies
and excrete extracellular polymeric substances (EPS), i.e. slime. The attachment becomes
irreversible. Stage 3: A biofilm is formed. It matures and cells form multi-layered
clusters. Stage 4: Three-dimensional growth and further maturation of the biofilm,
providing protection against host defense mechanisms and antibiotics. Stage 5: The
biofilm reaches a critical mass and disperses planktonic bacteria, ready to colonize other
surfaces [Citation: Monroe D (2007) Looking for Chinks in the Armor of Bacterial
Biofilms. PloS Biol 5 (11):e308. Doi: 10.1371/journal.pbio.0050307; Image Credit: D.
Davies; Copyright: © 2007 Don Monroe. This is an open-access article distributed under
the terms of the Creative Commons Attribution License, which permits unrestricted use,
distribution and reproduction in any medium, provided the original author and source are
credited.]
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1.1.4. Swarming and twitching motilities are multicellular behaviors
P. aeruginosa exhibits a large variety of translocation movements, including
swarming, swimming, twitching, gliding, sliding and darting.43 Among those different
translocation movements, swarming is regarded as a multicellular behavior. Swarming
bacteria move in multicellular groups and exhibit adaptive resistance to multiple
antibiotics.44-46 Both biofilm formation and swarming are surface-associated
multicellular bacterial activities that are inversely regulated.47-48 Swarming is a flagella
mediated rapid movement of bacteria on a semisolid surface.49-50 Some bacterial species
like Vibrio parahaemolyticus and Proteus mirabilis swarm on 1.5 to 3% of agar gel while
other bacteria like E. coli, P. aeruginosa and Bacillus subtilis swarm on 0.5 to 0.8 % agar
gel.44 Previous studies have suggested that quorum sensing, rhamnolipid production, type
IV pili, and the flagellum all contribute to swarming.46, 51 Quorum sensing control of
swarming is thought to be mediated by RhlR, which activates expression of
the rhlAB genes and these genes encode enzymes required for production of the
surfactant, rhamnolipid.52-53 While, some strains of P. aeruginosa when inoculated at the
center of a semisolid surface, grow outward from the point of inoculation to form
complexly branched tendrils, others simply grow outward from the point of inoculation
without forming any pattern.54 Figure 1.2 has shown the different type of swarming
pattern under similar swarming conditions. However, the formation of complex patterns
on the swarm gels is still being poorly understood.
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Figure 1.2 Swarm patterns of different P. aeruginosa strains on the semisolid surface
(0.5% agar).

Henrichsen and coworkers established that the mode of surface-associated
movement termed “twitching motility” is related to the presence of thin pili on various
bacterial species.55-56 They also found that strains exhibiting twitching motility form
“spreading and corroding colonies”.57 It has been shown that type IV pili are required for
twitching motility.58 Twitching motility is regarded as a result of the extension and
retraction of pili, which propels the bacteria across a surface.59-60
1.2. A brief history of antibiotic discovery and their classification

Throughout the human history, the fight against bacterial infections had never
stopped but the remedies for bacterial infections were often insufficient and for many
infectious diseases, there was no treatment available.61 Bacterial infections frequently led
to serious illnesses and caused high mortality rates. The revolution in antimicrobial
infection therapy began with the discovery of penicillin by Alexander Fleming in 1928.62
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The development of penicillin for medical use, and its enormously successful application
during the World War II led to a great interest in searching for other natural antibiotics.
Use of the whole cell antibacterial activity screening platform developed by Waksman
directed at a wide variety of fungi and bacteria led to the “golden age” of antibiotic
discovery.63

There are different ways to classify antibiotics, but the most common
classification methods are based on their molecular structures and spectrum of activity.64
Some common classes of antibiotics based on chemical or molecular structures include
Beta-lactams, Tetracyclines, Quinolones, Aminoglycosides, Macrolides, Sulphonamides,
Glycopeptides, and Oxazolidinones.65-67 Most of the antibiotics are targeting at a certain
unique feature of the bacterial structure or their metabolic processes completely different
or even not presented in mammalian cells.68-70 The common targets of antibiotics are
presented in Figure 1.3.71
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Figure 1.3 Sites of antibacterial action and mechanisms of resistance. Antibiotics can be
classified by their mechanism of action. DHF, dihydrofolic acid; LPS,
lipopolysaccharide; PABA, para-aminobenzoic acid; THF, tetrahydrofolic acid; TLR4,
Toll-like receptor 4. [Citation: Brown, D., Antibiotic resistance breakers: can repurposed
drugs fill the antibiotic discovery void? Nature Reviews Drug Discovery 2015, 14 (12),
821. doi: 10.1038/nrd4675. Epub 2015 Oct 23. This is an open-access article distributed
under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution and reproduction in any medium, provided the original author and source
are credited.]

1.3. Antibiotic resistance is a big problem
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The origin of antibiotics is ancient and antibiotic biosynthetic genes and
resistance-conferring genes date back to the ancient period.72 Thus, many
microorganisms have naturally been exposed to these antibiotics over evolutionary
timescales. It has been proposed that antibiotics have evolved to be global regulators
within microbial communities, contributing to quorum sensing and microbial
communication in the natural environment.73-74 At the low concentrations, antibiotics can
act as signaling molecules that trigger transcription responses important for
environmental survival.75-76 While the growth of surrounding microorganisms could be
inhibited at high concentrations of antibiotics are present.77 Since the first introduction of
antibiotics, bacteria over time have evolved sophisticated resistant strains against almost
all the available antibiotics which cause selection pressure on the bacteria to evolve their
genetic makeup and develop resistance against such agents.78-80 Combating such resistant
bacteria is an extremely difficult task if using antibiotics alone. Hence scientific
community continuously seeks new strategies to overpower these resistant bacteria.

1.4. Antibiotic adjuvants do not seem to eradicate the problem

An alternative strategy to combat bacterial infections is through using antibiotic
adjuvants, compounds that enhance the activity of current drugs and can minimize
resistance.81-83 In general, adjuvants are delivered together with antibiotics and therefore
are combination drugs which have been used to achieve synergy, cover the microbial
spectrum, and suppress resistance to enhance and preserve the activity of existing
drugs.84-87 Such synergistic effects are implying the greater efficacy of the combinations
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than the sum of the individual components. Antibiotic adjuvants can be divided into two
general classes based on target profile: Class I adjuvants that work with antibiotics on
bacterial targets (inactivating enzymes, efflux pump systems, or alternate targets), and
Class II adjuvants that enhance antibiotic activity in the host.88 The example of betalactamase inhibitors in the clinic over the past decades is proof that the antibiotic
adjuvants are powerful and important.89
The molecular basis of antibiotic synergy is poorly understood. However, without
mechanistic data, machine-learning strategies were applied to predict the efficacy of
combinations in the antifungal realm and to offer an opportunity to identify new
antibacterial combinations as well.90 Although there are adjuvant molecules that are
believed to have a reduced potential to elicit resistance from bacteria, so far do not seem
to eradicate the problem.

1.5. Our hypothesis: Controlling bacterial activities leads to eliminating antibiotic
tolerance and new persister formation

It is recognized that antibiotics that kill bacteria can also cause responses that,
over time, lead to bacterial drug resistance, making the treatment of infectious diseases
more challenging.8, 91 At sub-lethal concentrations, antibiotics can readily increase the
population of tolerant bacteria; these tolerant populations require a higher antibiotic
dosage to kill than typical susceptible bacteria.92 Studies also suggest that drug-tolerant
bacteria have a higher propensity to evolve into drug-resistant bacteria making antibiotics
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ineffective, even at a high dosage.93-94 Antibiotics can also enhance a pre-existing
population of bacteria, called persisters, which are non-growing and thus extremely
difficult to eradicate using current antibiotics.95-97
Luk lab has developed a class of molecules that inhibit both swarming motility
and biofilm formation by P. aeruginosa.98-99 In contrast, at low concentrations, the
antibiotic tobramycin, a front-line treatment for chronic infections associated with cystic
fibrosis (CF), increases swarming motility and biofilm formation by P. aeruginosa.100
This result prompted us to assess our molecules as a potential adjuvant agent to increase
the effectiveness of tobramycin. Preliminary results show our molecules enable
tobramycin to kill both planktonic bacteria and tolerant bacteria in a preformed biofilm
that was promoted by the sub-lethal concentration of tobramycin. Our molecules, in
combination with antibiotics, also eliminated newly formed persisters in a biofilm that
are induced upon exposure to antibiotic treatment. This finding is significant, as our
novel adjuvants will drastically improve the performance of existing antibiotics. Treating
antibiotic-resistant infections is a major medical concern; which this project can address.
In the following chapters, we will evaluate the ability of our adjuvant molecules to
eliminate drug-tolerant bacteria and to reduce persisters, in combination with antibiotics.
We have established growth conditions that generate tobramycin-tolerant bacteria and
tobramycin-induced persisters. Using these assays, our preliminary result shows that our
molecules enable tobramycin to kill tobramycin-tolerant bacteria, as well as to prevent
the formation of persisters.

12

1.6. A brief introduction of the following chapters
In Chapter 2, two efficient detection and quantification methods that make use of
the negative charges of the alginate polymer and do not involve degradation of the
targeted polysaccharide were described. Both approaches provide efficient methods for
monitoring alginate production by mucoid Pseudomonas aeruginosa.
In Chapter 3, the effect of a class of synthetic analogs of rhamnolipids at
controlling (promoting and inhibiting) the biofilm formation activities of a nonrhamnolipid-producing strain – rhlA – of Pseudomonas aeruginosa was described.
In Chapter 4, a class of disaccharide derivatives that can inhibit both swarming
motility and biofilm formation of Pseudomonas aeruginosa were described. Those
potential adjuvant agents can increase the effectiveness of antibiotics. In addition, the
ability of our adjuvant molecules to eliminate drug-tolerant bacteria and to reduce
persisters, in combination with antibiotics was demonstrated.
In Chapter 5, the binding property of a fluorophore-derivatized disaccharide to
LecA protein was demonstrated by fluorescent polarization assay. In addition, the
binding properties of synthetic molecules to LecA protein were demonstrated by
competitive fluorescent polarization assay.
In Chapter 6, the binding property of synthetic ligands to pili protein was
demonstrated by adding a functional group to a ligand that can covalently attach to the
receptor protein. In addition, the effect of externally added pili on the swarming motility
of Pseudomonas aeruginosa was tested to support the mechanistic study of the pili as the
receptor (or one of the receptors) that will bind to rhamnolipids and our synthetic agents,
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and upon binding, causing the bacterial activities. Together these results in chapter 5
suggest that SFβM is a chimeric ligand that binds to two different targets, LecA101-102 and
pili, and also explains why two distinct processes (biofilm formation and swarming) are
inhibited by the same molecule.
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Chapter 2 Quantification of alginate by aggregation induced by calcium ions and
fluorescent polycations

2.1. Introduction
2.1.1. Development of alginate quantification methods and its importance
Quantification of polysaccharides bearing negative charges, such as various
heparins and alginate, is important for understanding cell signaling for both mammalian
cells and bacteria.103-105 Various approaches such as colorimetric assays coupled with
covalent reactions, salt complex forming induced staining, aggregation,106 as well as
high-performance liquid chromatography-diode array detector methods107 have been
developed to achieve this goal. Recently, Correa and coworkers have demonstrated the
successful use of FT-IR spectroscopy to quantify alginate production by several
Pseudomonas fluorescens strains.108 The most commonly used carbazole assays involve
heating the polysaccharides with concentrated sulfuric acid followed by an addition of an
aromatic amine – carbazole. Carbazole-sulfuric acid method was first described by
Dische108 and further developed by Gurin and Hood109 for the identification and
estimation of hexoses and pentoses. Later, Bitter described a modification of the
carbazole method for the analysis of uronic acids, which is the major component of
alginate.110 Reactivity of several uronic acids and uronic acid-containing
mucopolysaccharides (MPS) was studied systematically at various temperatures and for
various heating periods.111 The study revealed that different uronic acids and MPS upon
heating with sulfuric acid produce products with different absorbance in the carbazole
assay.111 The acid treatment generates a range of chemical species starting with breaking
15

the glycoside bonds, generating the aldehyde that can react with the amine to form a
colored imine. Other chemical species from further decomposition such as furic acid
were reported, giving a chemically poorly defined mixture. A modification of the
carbazole reaction was obtained, in which the intensity of the color depends not only on
the structure of individual hexuronic acids but also on specific linkages in
polyuronides.112 Because of the harsh conditions, and dependence of the reaction on the
nature of the polysaccharide, carbazole-based assays have been reported to produce false
positives and inconsistent results for various polysaccharide structures.113 More
detrimental to the selectivity, both mono- and disaccharides react with the carbazole,
producing a high level of background noise that requires the purification of targeted
polysaccharides.
We are interested in the detection of alginates, polysaccharides with 1-4 linked Dmannuronic (M) and L-guluronic (G) acid residues that are produced by the opportunistic
bacterium Pseudomonas aeruginosa. This bacterium often resides in the lungs of patients
with cystic fibrosis who have mutations in cystic fibrosis transmembrane conductance
regulator (CFTR) protein, which can cause impaired ion transport.114 In the lungs of
patients with cystic fibrosis, P. aeruginosa rapidly converts to mucoid P. aeruginosa, a
phenotype that overproduces alginate. Thus, development of a direct method for the
detection of alginate without purification from the culture of mucoid phenotype is greatly
desired for the screening of chemical agents that can inhibit the production of alginate by
the pathogenic strain of P. aeruginosa.
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2.1.2. The aim of the chapter

In this chapter, we report two new approaches to detect the production of alginate.
In the first method, calcium ion is used to aggregate the alginate in situ without purifying
the alginate from the culture medium; the aggregates were hydrogel-like and quantified
by using the conventional crystal violet dye assay. In the second method, alginate
aggregation was induced by multivalent binding between a fluorescently-labeled
polycation and alginate. This approach (labeling the polycation) provides a sensitivity
comparable to that of the carbazole assay, but without the need for chemical reactions
and multiple steps of operations. we will describe two efficient detection and
quantification methods that make use of the negative charges of the alginate polymer and
do not involve degradation of the targeted polysaccharide. The first method utilizes
calcium ions to induce hydrogel-like aggregate with alginate polymer; the aggregates can
be readily quantified by staining with a crystal violet dye. This method does not require
the purification of alginate from the culture medium and can measure a large amount of
alginate that is produced by a mucoid Pseudomonas aeruginosa culture. The second
method employs polycations tethering a fluorescent dye to form suspension aggregates
with the alginate polyanion. Encasing the fluorescent dye in the aggregates provide an
increased scattering intensity with a sensitivity comparable to the conventional carbazole
assay. Both approaches provide efficient methods for monitoring the alginate production
by mucoid.
2.2. Results and discussion
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2.2.1. Design of alginate quantification methods by aggregation induced by calcium ions
and fluorescent polycations
P. aeruginosa is an opportunistic Gram-negative bacterium that can undergo
phenotypic changes to convert from the wild-type to a mucoid phenotype in the lungs of
immunocompromised individuals (e.g. with fibrosis patients).9, 115-116 This mucoid strain
is characterized by the overproduction of alginate polysaccharides, which are copolymers
of 1-4 linked D-mannuronic and L-guluronic acid residues.117 The adhesion of mucoid
alginate to the lung of a patient is a major virulence factor that causes a series of
problems including hosting dormant bacteria, reducing the effectiveness of antibiotics,
and difficulty in breathing.118 We are interested in developing methods for efficient
detection of alginate production by mucoid P. aeruginosa. Such methods are useful for
evaluating chemical agents that can inhibit alginate production by the mucoid strain.
The conventional carbazole assay does not take advantages or make use of the
existence of negative charges on the alginate polymer. Here, we explore the multiple
carboxylate groups in the alginate to enable aggregation and detection by using two
different approaches. First, we use calcium ion to form aggregates with alginates,
followed by crystal violet staining of the aggregate as a quantification means. Second, we
explore the aggregation induced by the multivalent binding between a polycation,
polyallylamine (PAA), and alginate in aqueous solutions (Figure 2.1). To increase the
sensitivity of this method, we also covalently modified PAA with fluorescein
isothiocyanate (FITC), a fluorescent fluorophore. Polyallylamine (PAA) tethered with
FITC has been used in many applications, including the photophysical study of
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fluorescent core nanoparticles fabricated by the layer-by-layer assembly,119 probes for
TNT detection based on FRET120 and colloidal DNA carriers.121

Calcium alginate
aggregate

A. Sodium alginate
2+

Ca

B. Sodium alginate

PAA-FITC

PAA-FITC alginate
aggregate

+
: Fluorescein isothiocyanate
group
Figure 2.1 Schematic representation of aggregate formation between (A). Alginate and
calcium ions, (B). Polyallylamine (PAA)-FITC and alginate.

Calcium and other divalent metal ions have long been recognized to form an
aggregate with alginate polymers due to the chelation of the carboxylate groups of the
polymer with calcium.122 The direct detection of these aggregates, however, has not been
explored. Here, we first examine the effect of calcium ion present in growth medium
alone for bacterial culture to evaluate the background noise, if any, from calcium ion in
the LB broth. Figure 3 shows that, after treatments with Ca2+, sodium alginate and
mucoid P. aeruginosa grown in LB broth media form aggregates, while LB broth media
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itself and wild-type P. aeruginosa PAO1 grown in LB broth media do not show any
aggregate after Ca2+ treatment (Figure 2.2). This result suggests that calcium ion does not
cause any aggregation in LB broth alone but causes aggregation for both purchased
sodium alginate and the alginate produced by mucoid P. aeruginosa.
Upon adding calcium chloride, the mucoid P. aeruginosa culture exhibits the
formation of large aggregates. After centrifugation of this culture solution, we observed
cell pellets at the bottom of the falcon tube. In the solution above the cell pellets, large
hydrogel-like calcium alginates are observed. The calcium alginate was recollected by
pouring out the supernatant along with the hydrogel-like aggregate; the cell pellet was
left behind and discarded.
A

B

C

D

Figure 2.2 Pictures of (A) 2 mL of 6 mM CaCl2 mixed with 200 µL of 5 mg/mL of
sodium alginate; (B) 500 µL of 60 mM CaCl2 mixed with 5 mL of LB broth media; (C)
500 µL of 60 mM CaCl2 mixed with 5 mL mucoid P. aeruginosa (OD=0.7) grown in LB
broth media; and (D) 500 µL of 60 mM CaCl2 mixed with 5 mL wild-type P. aeruginosa
PAO1 (OD=0.7) grown in LB broth media. Before adding CaCl2, the solution was
centrifuged; and the bacteria pellets were removed.
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We quantified the resulting aggregates by staining them with a crystal violet dye –
a common staining agent.123 To establish the concentration dependence, we studied the
optical density of aggregates formed between calcium and commercially available
sodium alginate with a series of concentrations from 0.1 mg/mL to 2 mg/mL. A linear
correlation between 0.2 mg/mL to 2 mg/mL are readily obtained (Figure 2.3). However,
the signal is rather weak when the concentration of alginate is lower than 0.2 mg/mL
(corresponding to an OD value of 0.04 for 0.2 mg/mL of alginate).
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OD600 of dyed alginate
dissolved in 3% AcOH
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Figure 2.3 Optical density at 600 nm of calcium alginate by crystal violet dye staining
assay
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2.2.2. Quantification of by alginate produced by mucoid P. aeruginosa

Next, using this linear relationship, we quantified alginate produced by mucoid P.
aeruginosa over the span of 24 h culture. In this study, we used a mucoid phenotype
(PA2192) isolated from CF patients. Goldberg and coworkers revealed the differences
between proteins expressed by CF isolates of P. aeruginosa that have phenotypes
associated with the initial versus chronic infection process.124 Figure 2.4.A shows the
growth curve of mucoid P. aeruginosa in 24 h, Figure 2.4.B shows the corresponding
alginate production in mg/mL determined by using crystal violates dye staining assay.
Our result showed that mucoid P. aeruginosa did not produce any noticeable amount of
alginate in the first 2 hours, but measurable amount of alginate was observed after 3
hours. This result is consistent with the notion that significant alginate production by
mucoid P. aeruginosa starts in the exponential growth period and reaches a plateau after 7
hours when the bacterial growth slows down.

22

OD600 of Muc PA culture

A.
1.4
1.2
1
0.8
0.6
0.4
0.2
0

Alginate produced by
Muc PA (mg/mL)

B.

0 2 4 6 8 10 12 14 16 18 20 22 24
Time/h
2
1.5
1
0.5
0
0 2 4 6 8 10 12 14 16 18 20 22 24
Time/h

Figure 2.4 Plot of (A) the mucoid P. aeruginosa growth curve, and (B) the optical
density of Ca2+ induced aggregation of mucoid alginate by using crystal violate dye
staining assay, versus time of culture. The bacterial culture was grown in LB broth media
shook at 250 rpm.
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2.2.3. Comparison of different alginate quantification methods
Comparing to the carbazole assay, the calcium aggregation-CV staining method
can directly measure 0.05 mg/mL (or more) alginates without dilution and without
purification, which is well-suited for monitoring the alginate production by mucoid P.
aeruginosa. More importantly, the calcium aggregation method does not have a
background signal for pure LB broth medium, for carbazole assays, however, a
background signal of the optical density of ~0.12 for pure LB broth was observed. This
value is comparable to the signal from 0.04 mg/mL of sodium alginate in water (Figure
2.5 and Figure 2.6). However, the sensitivity of measuring the optical density of calciumalginate aggregation (not staining method) is limited to about 0.2 mg/mL of alginate in
solution.
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OD540
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Figure 2.5 Optical density at 540 nm of sodium alginate aqueous solution (0~1.0 mg/mL)
by carbazole assay
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Figure 2.6 Optical density at 540 nm of 0 mg/mL, 0.02 mg/mL, 0.04 mg/mL sodium
alginate aqueous solution and LB broth media by carbazole assay

Considering this low sensitivity, we explored the use of a polycation to aggregate
alginate. Polycations readily form aggregates with polyanions through multivalent
binding. This aggregation effect is used in various applications, including layer-by-layer
deposition of polyelectrolytes125 and medical and pharmaceutical applications like selfassembled shells for drug delivery.126 By mixing 2 mL of poly allylamine (0.5 mg/mL)
and 200 µL of sodium alginate (0.5 mg/mL), a cloudy and stable suspension solution was
obtained (Figure 2.7), rather than a hydrogel-like aggregate. Because the suspension is
stable, we measured the optical density directly to correlate to the amount of alginate
present in the solution. Sodium alginate in solution forms aggregates by mixing with a
CaCl2 or PAA solution. However, our method shows that using a solution of CaCl2 or
PAA, the optical density value was less than 0.16 when the sodium alginate concentration
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is 0.50 mg/mL (Figure 2.5), whereas, for carbazole assay, the optical density is around 1.0
for the same sodium alginate concentration. Thus, the sensitivity of these two methods is
still low, and not comparable to carbazole assay.

A

B

Figure 2.7 Pictures of the solution of 2 mL of 0.5 mg/mL of PAA (A) mixed with 200 µL
of 5 mg/mL of sodium alginate to form aggregates (B).

To improve the sensitivity of an aggregation assay, we grafted a fluorophore onto
the polycation to explore an increase in the optical density signal. As the intensity of the
light scattering depends on the induced dipoles in the particles – a phenomenon less
explored for applications, we believe that introducing polarizable groups into the
aggregates will increase the polarizability of the particle, and thus may increase the signal
intensity. Furthermore, as the fluorophores are confined in the aggregates, a coherent
scattering is possible, which further increases the scattering. Mixing alginate with
fluorescent polycations resulted in a similarly stable suspension of aggregates (inset of
Figure 2.8). Measuring the UV-Vis spectra of different concentrations of sodium alginate
in the presence of 0.5 mg/mL PAA-FITC showed a band at 495 nm, which decreased as
the concentrations of added sodium alginate were increased. Interestingly, the baseline of
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the UV intensity from 250 to about 850 nm increased significantly with the concentration
of added sodium alginate. This result is consistent with increased light scattering due to
the fluorescent aggregates. To measure the light scattering, we plotted the optical density
at 405 nm (OD405) of the solution mixtures with different sodium alginate concentrations
(0.01~0.50 mg/mL). A linear relation between the optical density and the alginate
concentration was obtained (Figure 2.9). Comparing to the optical density obtained from
polyallylamine (without fluorescent labeling) and alginate, this result indicates that
fluorescent aggregates increase the intensity of optical density measurement. Thus, this
fluorescent polycation enables a more sensitive method for detecting targeted molecules
through aggregation.
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Figure 2.8 UV-Vis Spectra of different concentrations of sodium alginate in the presence
of 0.05 mg/mL PAA-FITC. The pictures of the solution of 2 mL 0.5 mg/mL of PAAFITC (A) and the solution of 2 mL 0.5 mg/mL of PAA-FITC mixed with 200 µL of 5
mg/mL of sodium alginate to form aggregates (B) are also shown.
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Figure 2.9 includes the signals for optical absorption of the carbazole dye reacted
with the decomposed alginate, optical density of aggregation with PAA-FITC, PAA, and
calcium chloride as a function of the concentration of sodium alginate. At relatively high
concentration, 0.5 mg/mL, aggregation with CaCl2 and PAA showed an optical signal less
than 0.2, whereas aggregation with PAA-FITC and carbazole assay showed optical
signals above 0.8. These results indicate that aggregation with PAA-FITC and carbazole
assay offer a larger signal range than aggregation with CaCl2 or PAA. This result also
indicated that aggregation using PAA-FITC has a comparable sensitivity to the carbazole
assay, the conventional method for detecting alginate. However, aggregation with PAAFITC does not require multiple steps of covalent reactions. This simplification increases
the ease of the operation and the reliability of the results, as the reaction yields of the
covalent reactions become irrelevant.
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Figure 2.9 Plot of optical density (OD405) of sodium alginate aqueous solution treated
with 6 mM of CaCl2, 0.5 mg/mL of PAA, or 0.5 mg/mL of PAA-FITC solution; and the
optical absorption (at 540 nm) of carbazole dye reacted with decomposed alginate.

2.3. Conclusion

To conclude, we demonstrated two efficient methods for detecting and
quantifying alginate polymer in a solution. The calcium aggregation-staining assay stains
directly the calcium-alginate aggregates formed in a bacterial culture without purification
and provides a one-step detection/quantification method. This assay has a dynamic range
(0.05 mg/mL and up) that is suitable for monitoring and quantifying the alginate
production by mucoid P. aeruginosa directly from an LB broth culture over 24 h. Using
polycations tethered with fluorescent dyes, we obtained the sensitivity that is similar to
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carbazole assay. To conclude, the calcium aggregation-staining method does not require
the purification and can be used directly for detecting the alginate produced by a mucoid
P. aeruginosa culture, whereas aggregation by fluorescently labeled polycations provides
similar sensitivity to conventional carbazole assays; and both methods do not require
covalent reactions and multiple steps of operations.

2.4. Materials and methods

2.4.1. Bacterial strains and growth media

Wild-type P. aeruginosa, PAO1 were obtained from Dr. Guirong Wang (Upstate
Medical University). Mucoid P. aeruginosa strain PA2192 was isolated from CF patients
by Dr. Goldberg at Emory University.27, 28 All the bacterial strains were grown in LuriaBertani (LB) medium containing 10 g/L tryptone, 5 g/L yeast extract, and 10 g/L NaCl at
37 °C.

2.4.2. Synthesis of PAA-FITC29

Fluorescein isothiocyanate (FITC) was dissolved in dimethyl sulfoxide (final
concentration of 1 mg/mL) and protected from light by wrapping the tube in aluminum
foil. The FITC solution (40 µL) was then added to each milliliter of a 2 mg/mL
polyallylamine (PAA, average Mw ~17,500) solution of pH ≈ 10 so that the FITC to 30

NH2 monomer ratio was 1:50. The mixture was gently stirred and allowed to react at 4 °C
overnight. The PAA-FITC product was purified by adding acetone to the reaction mixture
resulting in the precipitation of the product forming a cloudy solution. After centrifuged
at 8.5 x 103 rpm for 10 min, a reddish-brown precipitate was observed, and the solution
was discarded. The precipitates were further washed with acetone and dried overnight by
vacuum. By comparing the neat UV absorption of FITC in 1:1 MeOH/H2O solution and
PAA-FITC product in 1:1 MeOH/H2O solution, we have confirmed there is no
observable unreacted FITC in either the precipitate product or in the solution, or in the
reaction mixture before precipitation. The reaction is quantitative, and the ratio of FITC
to the monomers of PAA is 1 to 50. Thus, the degree of labeling (DOA) is 3.76 FITC per
polymer of PAA, which contains an average of 188 monomers.

Figure 2.10 Synthesis of PAA-FITC
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2.4.3. Quantification of alginate by crystal violet dyed glycolipid assay

A solution of 500 µL CaCl2 (60 mM) was added to 5 mL of neutral (pH 7.0)
aqueous solution containing known concentrations of sodium alginate. A hydrogel-like
suspending aggregate was observed. The mixture was centrifuged at 5600 rpm for 5 min.
The supernatant was removed by discarding the solution while using a glass rod to
prevent alginate aggregate from falling out. The alginate aggregate was then rinsed 3
times with deionized water (18 mΩ) to obtain a wet alginate. The alginate aggregate was
soaked in 500 µL of 0.3 % crystal violet (CV) dye aqueous solution for 20 min. The CV
dye solution was discarded, and the alginate was rinsed 3 times with deionized water. The
absorbed CV dye was then extracted from the aggregate by 5 mL acetic acid and gently
shaking. The optical density of the dye solution is measured by using 100 µL with a 96well plate on a Biotek ELx800 Absorbance Microplate Reader at a wavelength of 600
nm.

2.4.4. Quantification of alginate by direct optical density measurement assay

Stock solutions of 60 mM CaCl2, 0.5 mg/mL PAA and 0.5 mg/mL PAA-FITC
solution are prepared. Stock solutions (100 µL of CaCl2, PAA or PAA-FITC) were mixed
with 1 mL of sodium alginate aqueous solution with known concentrations by using a
vortex mixer. The optical density of the solutions was measured by using 100 µL in a 96-
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well plate on a Biotek ELx800 Absorbance Microplate Reader at a wavelength of 600
nm.

2.4.5. Carbazole assay

Carbazole assay was performed as described by A. M. Chakrabarty and
coworkers, with slight modifications.25 Briefly, a borate stock solution was prepared by
diluting 24.7 g of H3BO3 in 45 mL of 4 M KOH to a total of 100 mL using sterile water.
Before every use, a borate working solution was prepared by mixing 1 part of the borate
stock solution with 40 parts of 98% H2SO4, and a 0.1 wt % carbazole solution was
prepared in ethanol. Before doing the assay, the borate working solution was put in an
ice-water bath for 10 min. A 70 µL of sodium alginate sample with known concentrations
(0.01 to 1.00 mg/mL) was added onto the ice-cold borate working solution. Two layers of
the solution were observed; the solution (sample mixture) was for about 4 sec by using a
vortex and put back to the ice-water bath. A carbazole solution (20 µL) was added onto
the sample mixture and warmed at 55 °C for 30 min. The absorbance at 530nm was
measured. The standard curve was derived by plotting absorbance against the
concentration of sodium alginate ranging from 0.01 to 1.00 mg/mL.
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Chapter 3 Synthetic Analogs of Rhamnolipids Modulate Structured Biofilms
Formed by Rhamnolipid-nonproducing Mutant of Pseudomonas aeruginosa

3.1. Introduction
3.1.1. The importance of rhamnolipids and its analogs on biofilm structure

Bacterial biofilm is the source of infectious diseases in many contexts, including
in human hosts with compromised immune systems, and on a wide variety of surfaces in
contact with aqueous solutions.127-130 These bacterial biofilms consist of sophisticated
internal structures including pore and channels, mushroom and pillar-like structures,131-132
heterogeneous distribution of secreted chemicals and bacteria strains.133 The biology of
forming such structured biofilms is complex, and not well understood for a wide range of
microbes. For Pseudomonas aeruginosa, a class of molecules called rhamnolipids are
secreted; the presence of these secreted molecules are critical for forming structured
biofilms with pore and channels.134-137 When the biofilms age, rhamnolipids are also
needed for dispersion of bacteria from the biofilm.138-140 In addition, this class of
molecules, rhamnolipids, is also required for the swarming motility of P. aeruginosa on
an aqueous soft gel surface.46, 141-142 Interestingly, while biologists have established how
rhamnolipids are produced 143-145 and regulated146-147 in the bacteria and have identified
many, if not all, of the bio-functions of rhamnolipids, we still do not know the
mechanism of how rhamnolipids build such structured biofilm or enable and facilitate the
swarming motility of the bacteria. One of the challenges is that rhamnolipids are
surfactants, and thus, it is not clear if the mechanism of their functions is just physical –
by reducing the surface tension; or is biological – by having one or more specific
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receptors, the binding of which triggers a series of chemical signaling events that control
these activities; or whether both physical and biological mechanisms are involved.141-142

Recently, we have demonstrated that some synthetic molecules with a polar head
group and an aliphatic chain can reinitiate and promote the swarming activities of rhlA –
a mutant of P. aeruginosa that does not produce rhamnolipids, and thus does not
swarm.148-149 While these synthetic molecules are also surfactants, the potent members
inhibit the swarming motility of the wild-type Pseudomonas aeruginosa (PAO1). This
result, along with other findings, suggests that the mechanism of rhamnolipids and these
synthetic analogs are unlikely to be physical or a surfactant effect because our molecules
can also reduce the surface tension, and would offer the same physical mechanism
argument. The activities of swarming modulation (promotion and inhibition) are
extremely sensitive to the molecular details while all molecules resemble surfactant
structure and show surface activities. In addition, synthetic molecules with intermediate
potency exhibited oscillation in their bioactivities (promoting and inhibiting swarming
motility) as a function of concentration in the soft gel. This oscillation of bioactivities is a
strong indication of cell signaling events responding to an external stimulus.150-151
Furthermore, novel biological phenomena were observed. Synthetic molecules with
intermediate potency at controlling swarming motility induce tendril formation in the
swarming pattern152 suggesting the formation of two opposite phenotypes –
hyperswarming and lazy-swarming – while abandoning the original phenotype.148 Thus,
this class of synthetic molecules represents a class of chemical signals.148-149 While these
findings have focused on the influences on swarming motilities, in this work, we
demonstrate that synthetic analogs of rhamnolipids, at different concentrations, promote
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biofilm formation, help build structured biofilm, as well as inhibit the biofilm formation
by a mutant of Pseudomonas aeruginosa – rhlA – that does not produce rhamnolipids and
forms non-structured and thin biofilms.

3.1.2. The aim of the chapter

In this chapter, we explore the effect of a class of synthetic analogs of
rhamnolipids at controlling (promoting and inhibiting) the biofilm formation activities of
a non-rhamnolipid-producing strain – rhlA – of P. aeruginosa. This class of rhamnolipid
analogs is known to modulate the swarming motilities of wild-type PAO1 and rhlA
mutant, but its effect on biofilm formation of the rhlA mutant is unknown. We show that
small structural details of these molecules are important for the bioactivities, but do not
affect the general physical properties of the molecules. The bioactive synthetic analogs of
rhamnolipids promote biofilm formation by rhlA mutant at low concentrations but inhibit
the biofilm formation at high concentrations. To explore the internal structures formed by
the biofilms, we first demonstrate that wild-type biofilms are formed with substantial
topography (hills and valleys) when the sample is under shaking conditions. Using this
observation as a comparison, we found that synthetic analogs of rhamnolipids promoted
structured (porous) biofilm of rhlA mutant, at intermediate concentrations between the
low ones that promoted biofilm formation and the high ones that inhibited biofilm
formation. This study suggests a potential chemical signaling approach to control
multiple bacterial activities.

3.2. Results and discussion
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3.2.1. Structural considerations for rhamnolipids analogs

We choose six disaccharide-hydrocarbons to explore their activities in controlling
the biofilm formation by rhlA mutant (Figure 3.1). These synthetic molecules consist of a
disaccharide moiety tethered with various single aliphatic chains. We note that while
these small molecules do not bear significant structural similarity to rhamnolipids,
depending on the specific structures, they can mimic or dominate the activities of
rhamnolipids at controlling swarming motilities.148-149 Two of these molecules, saturated
farnesyl-β-maltoside (SFβM) and saturated farnesyl-β-cellobioside (SFβC), are strong
inhibitors of the swarming motility of PAO1 strain; and do not initiate swarming by rhlA
mutant, and are strong inhibitors of biofilm formation by PAO1 strain.148 Two of them,
dodecyl-β-maltoside (DβM) and benzophenonedecyl-β-maltoside (BPDeβM), promote
swarming of rhlA mutant and can cause tendril formation at specific concentrations in the
soft gel; they are also an intermediate inhibitor of biofilm formation relative to the
saturated farnesol derivatives.149 Here, we explore two more new structures, with the
introduction of an ether linkage in the two different positions in eleven-carbon aliphatic
chains that are tethered with a cellobioside, C6OC5βC, and C3OC8βC. These two
structures allow us to explore the effect of other functional groups (ether) rather than just
hydrocarbons at controlling the activities of P. aeruginosa.
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Figure 3.1 Structures of rhamnolipids and their analogs with disaccharide maltose (M) or
cellobiose (C) tethered with different aliphatic chains.

3.2.2. Active synthetic analogs of rhamnolipids stimulate and then inhibit biofilm
formation by rhlA mutants

We first use the traditional crystal violet staining assay to characterize the total amount of
biofilm formed by the rhlA mutant in the presence of different concentrations of the six
disaccharide hydrocarbons. Interestingly, for DβM, BPDeβM, SFβM, and SFβC,
promotion of the biofilm formed by rhlA mutants is observed as the concentration is
increased from 20 µM to 170 µM, in 24 h under non-shaking condition. The inhibition of
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biofilm formation is observed, most noticeably for SFβM and SFβC, when the
concentration is further increased to 340 µM (Figure 3.2A). For C6OC5βC and C3OC8βC,
there is no noticeable change in the amount of biofilm formed over the entire range of
concentrations studied, in comparison to the control, to which there are no agents added.

To examine the effect of our rhamnolipids-analogs at reducing the count of
bacteria from the biofilm as a consequence of biofilm inhibition, we dried the 24-h old
biofilm of rhlA mutant, and reintroduced fresh media, and measured the optical density
of the media that contained bacteria from the biofilm. At relatively low concentrations
(20 µM and 40 µM), DβM, BPDeβM, SFβM, and SFβC have no significant effect on the
bacteria in the biofilm, while at 340 µM, the number of bacteria from the biofilm is
reduced almost by half. For C6OC5βC and C3OC8βC, there is no noticeable change in the
number of bacteria that remained in the biofilm (Figure 3.2B). These results are
consistent with the corresponding amount of biofilm inhibited (Figure 3.2A).
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Figure 3.2 The percentages of biofilm that remained (A) were obtained by comparing
biofilm content treated with an agent to the control (without agents). The percentages of
bacteria from a 24-h old rhlA mutant biofilm (B) were obtained by comparing the OD600
of LB media in contact with rhlA biofilm without our agents (control) to that with our
agents under identical conditions. Added agents from left to right are I. DβM, II. SFβM,
III. SFβC, IV. BPDeβM, V. C6OC5Βc, VI. C3OC8βC. Error bar is the standard error of
the mean from six replicates.
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For inhibiting the biofilm formation, the effective concentrations for the rhlA
mutant (340 µM), are considerably higher than for wild-type PAO1. Considering this
high concentration, we examined the growth of the rhlA mutant in the presence of the six
molecules. At both 20 µM and 340 µM (Figure 3.3), these agents did not exhibit any
significant influence on the growth of rhlA mutant of P. aeruginosa in shaking culture
media. This result indicates that the mechanism of biofilm inhibition is not due to any
bactericidal effect, but rather likely due to the interference of a ligand-receptor binding
that triggers signaling events.
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Figure 3.3 rhlA mutant of P. aeruginosa growth–response curve with and without 20
µM(A) or 340 µM(B) rhamnolipids analogs. Error bar is the standard error of the mean
from six replicates.
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Because rhlA mutant, which does not produce rhamnolipids, forms a nonporous
biofilm, rhamnolipids are implicated in the formation of porous biofilm.134 However, the
exact mechanism of how rhamnolipids help create such a porous biofilm is not clear yet.
We have previously shown that externally added rhamnolipids had only a mild effect on
inhibiting biofilm formation of PAO1 strain.149 Together with the fact that rhlA mutant
form biofilms slower and form thinner biofilms than a PAO1 strain, rhamnolipids are
required for efficient formation of full biofilms. Thus, we believe that, in a biofilm
growth experiment, a significant amount of synthetic analogs of rhamnolipids are first
used to facilitate efficient formation of biofilm; only when the full biofilm is formed,
additionally added rhamnolipids-analogs may then start to inhibit the formation of
biofilm. Thus, this strong requirement of rhamnolipids or rhamnolipid-analogs for
biofilm formation caused a high concentration requirement for the rhamnolipid-analogs
to exhibit biofilm inhibition activities for rhlA mutants. The mechanism of how
rhamnolipids or its analogs are facilitating the biofilm formation is still not clear. As
these molecules are likely causing cell signaling events, we believe that the presence of
these ligands is changing the expression level of their receptors.

We have previously demonstrated that synthetic agents that are active for
controlling swarming motility may or may not be active for inhibiting biofilm formation.
For example, saturated farnesol tethered with tetra(ethylene glycol) inhibits swarming but
not biofilm formation, whereas saturated farnesol tethered with disaccharides strongly
inhibits both swarming and biofilm formation.149 Furthermore, swarming motilities is
sensitive to the agents’ concentrations, in that oscillation in swarming activities is
exhibited as the concentration increases. For these reasons, we carried out a detailed
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concentration study on the effect of ether-linked disaccharides (C6OC5βC and C3OC8βC)
on the swarming motility of PAO1 and rhlA mutants. For controls, we used DβM with
more expanded concentration ranges than that previously studied.148-149 Figure 4 shows
that while DβM activated swarming of rhlA and further caused tendril formation in the
swarming pattern, C6OC5βC did not show a noticeable effect for influencing the
swarming motilities of rhlA mutant. For PAO1, C6OC5βC also did not show any
noticeable effect on swarming, but expanded concentrations of DβM indicated slight
promotion of swarming at about 50 µM and caused tendril formation at 85 µM or higher
(Figure 3.4). Wild-type P. aeruginosa, PAO1, does not form tendrils on its own.
Together with the sensitivity to the chemical agents’ structural details, this chemically
induced tendril formation suggests a ligand-receptor binding event for DβM. We note
that C3OC8βC is also not active (Figure 3.5). Thus, ether-linked disaccharides are not
active for controlling either swarming or biofilm formation. These results suggest that the
structures of the aliphatic chains play a critical role in controlling the bioactivities of the
molecules.
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Figure 3.4 Swarming patterns (A) and the plots of swarming areas of rhlA and PAO1
strains on the soft gel (0.5 wt% agar) containing different concentrations of DβM and
C6OC5βC. Controls contain no added synthetic agents. The concentrations are shown
above the swarming images. Images were taken 24 h after inoculation of bacteria at the
center of the plate.
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Figure 3.5 Swarming of PAO1 and rhlA on the soft gel (0.5% agar) with the presence of
different concentrations of (A) C6OC5βC and (B) C3OC8βC. Compounds do not promote
swarming of rhlA or promote tendril formation in PAO1. Bacteria were inoculated at the
center of the semisolid gels (~0.5 % agar). Pictures were taken 24 h after inoculation with
bacteria.

3.2.3. Shaking produces structured biofilms by PAO1 strain

To explore whether our synthetic analogs can produce structured biofilms, in
addition to promoting biofilm formation, we first explore conditions that will give
structured and less-structured biofilms. It is known that flow of media can enhance the
production of structured biofilms with channels, pores, and in general, with a high degree
of topography.131, 133, 137 Tolker-Nielsen and coworkers have reported that in under flow
conditions, biofilms were formed with channels and pores.131, 133 Unfortunately, for
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synthetic analogs, the number of agents we obtain from organic synthesis is quite limited
in comparison to the amount needed for continuous flowing of agent-contained media
that last for hours to days. For this reason, we seek a different and new condition that
would allow us to explore the effect of our agents on the structure of the biofilm formed
by the rhlA mutant. To create a dynamic condition of the media, but without flow, we
explored shaking of the 96-well plate, in which biofilm is formed, to examine the
structures (pores and channels) of biofilm with and without such shaking agitation.

We first tagged PAO1 and rhlA strains with plasmid pSMC2 that constitutively
expresses the green fluorescent protein,153 and then examined the biofilms formed by
these bacteria with and without shaking. Figure 3.6 shows that PAO1 formed a flat and
thick bed of biofilm in the non-shaking condition. Shaking the plates with 100 rpm,
PAO1 biofilm exhibited distinct features that resembled structured biofilm, including
topography of hill and valley-like structures in the confocal fluorescent signals, instead of
a plain flat biofilm. However, rhlA mutant formed flat and thinner biofilm with and
without shaking. This result indicates that shaking at 100 rpm produce a highly structured
biofilm by PAO1. For the rhlA mutant, this strain produced significantly less biofilm than
PAO1 strains, and the biomass with and without shaking is at a similar level. The
mechanism, whether physical or biological in nature, is unknown for how shaking
induces the formation of such structured biofilm of P. aeruginosa. Considering the
drastic structural difference in the PAO1 biofilm produced with and without shaking, we
used these two kinds of biofilm as standards to compare and evaluate the degree of
structural features of biofilms formed by the rhlA mutant that is stimulated by the
presence of our synthetic analogs.
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Figure 3.6 The effect of shaking (non-shaking and 100 rpm) on biofilm formation by the
rhlA mutant of P. aeruginosa in 24h. Representative confocal laser scan microscopy
(CLSM) images (A) of biofilm formed by rhlA- EGFP mutant (plasmid pSMC2 that
expresses green fluorescent protein). Scale bar = 76 µm.

3.2.4. Synthetic analogs of rhamnolipids induce structured biofilm formed by rhlA mutant

Next, we examined the influence of synthetic analogs of rhamnolipids on biofilm
structures of rhlA-EGFP strain formed under non-shaking conditions by using confocal
fluorescence. At 24 h, there is visibly more fluorescence signal for biofilm formed by the
rhlA-EGFP strain which was treated with 20 µM of all four agents, DβM, BPDeβM,
SFβM, and SFβC, than biofilm formed without any added agents. Among these agenttreated biofilms, BPDeβM caused the most biofilms. When we examined the same
biofilms but treated with 340 µM instead of 20 µM of the four agents, each biofilm
sample formed by rhlA-EGFP strain showed less fluorescent signal than the control
biofilm that had no added agents (Figure 3.7). These results suggest that at 340 µM, all
four agents, DβM, BPDeβM, SFβM, and SFβC, are inhibiting the biofilm formation. To
confirm these results – promotion at 20 µM and inhibition at 340 µM – we examined the
biofilm formed by the rhlA-EGFP strain with the same agent treatments (20 and 340 µM)
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after 48 hours of culture. Overall, more biofilm was observed for all samples. For
BPDeβM, SFβM, and SFβC, more biofilms were observed for samples containing 20 µM
of agents than the control sample without agent treatment; however, significantly less
biofilm was observed for samples containing 340 µM of agent than the control. These
results suggest that BPDeβM, SFβM, and SFβC inhibited biofilm at 340 µM. The agent
DβM did show a slight promotion of biofilm at 20 µM, but a comparable amount of
biofilms were observed at 340 µM. To quantify the amount of biomass of the biofilm,
software COMSTAT was used. According to the COMSTAT-based quantification of
biomass, 10 % ~ 60 % biofilm promotion was observed for the biofilm samples
containing relatively low concentrations of agents (20 µM and 40 µM). While at 340 µM,
around 80 % of the biofilms were inhibited by DβM, BPDeβM, SFβM, and SFβC.
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Figure 3.7 The effect of rhamnolipid analogs on biofilm formation by the rhlA mutant of
P. aeruginosa (A) in 24 h, and (B) in 48 h under 100 rpm shaking condition.
Representative confocal laser scan microscopy (CLSM) images of biofilm formed by
rhlA-EGFP strain (plasmid pSMC2 that expresses green fluorescence). Scale bar = 76
µm.

We note that in a 24 well-Plate under shaking conditions, the biofilm formed by
the rhlA mutant in the presence of saturated farnesol agents exhibited a conspicuously
different appearance than the biofilm formed without added agents. Without added
agents, the biofilms formed by rhlA mutant appeared to have more exopolymers covering
the bottom of the wells, whereas, with SFβM at both low (20 µM) and high (85 µM)
concentrations, there were fewer exopolymers covering the bottom of the wells (Figure
3.8). For C6OC5βC and C3OC8βC, there is no significant change in the number of
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fluorescent signals in the biofilm formed by rhlA-EGFP strain as compared to the control
that has no added agents (Figure 3.9).

Figure 3.8 Treatment of rhamnolipids analogs on rhlA mutant affects the appearance of
biofilm formed on 24 well plates under non-shaking condition.

Figure 3.9 The effect of rhamnolipids analogs on biofilm formation by the rhlA mutant of
P. aeruginosa in 48 h under 100 rpm shaking condition. Representative confocal laser
scan microscopy (CLSM) images of biofilm formed by rhlA-EGFP (plasmid pSMC2 that
expresses green fluorescence). Scale bar = 76 µm.
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Next, we examined the biofilm formed by the rhlA mutant with intermediate
concentrations between the low concentrations that caused the initial promotion and the
high concentrations that caused the biofilm inhibition. To our surprise, at intermediate
concentrations, the synthetic analogs SFβM (40 µM), SFβC (40 µM), and BPDeβm (40
µM) promoted biofilms formed by rhlA mutant to exhibit structural features of porosity
more resembling the structured PAO1 biofilm formed under shaking than that without
shaking (Figure 3.10). Without shaking, these structural features in the biofilm of rhlA
mutant are likely caused by the presence of synthetic analogs rather than any other
physical effect.

Figure 3.10 The effect of synthetic analogs of rhamnolipids on biofilm formation by the
rhlA mutant of P. aeruginosa in 24 h under non-shaking condition. Representative
confocal laser scan microscopy (CLSM) images of biofilm formed by rhlA- EGFP strain
(expresses green fluorescence on plasmid pSMC2). Scale bar = 76 µm.
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Wild-type PAO1 produces rhamnolipids, and under a flowing fluid8 or shaking
conditions, produces highly structured biofilms with channels. For rhlA mutant which
does not produce rhamnolipid, however, our shaking experiment does not cause the
bacteria to produce structured biofilm. Instead, two notable rhamnolipid analogs, SFβM
and SFβC, at intermediate concentrations enabled rhlA mutant to make structured
biofilms without shaking or under a flowing fluid. Figure 3.11 summarizes the effect of
active synthetic analogs on biofilm structures of rhlA mutants. These fluid-filled voids
give rise to the complex structure in a biofilm including pores and channels. Such
structures are believed to be responsible for nutrient transport, cell-cell interactions, and
even to support a degree of homeostasis.36 The mechanism for the formation of these
structures is still unclear although we know that rhamnolipids, and also its synthetic
analogs, play a critical role.

Figure 3.11 Schematic representation of synthetic analogs of rhamnolipids at modulating
biofilm formed by the rhlA mutant.

Biofilm formation and swarming motility are both multi-cellular activities, and
many of these multi-cellular activities are initiated or regulated by quorum sensing.154-156
Here, we believe that both biofilm formation and swarming motility are also controlled
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by chemical cues or signals such as rhamnolipids from the environment. These signals
directly control whether swarming motility will occur or not, and what types of the
internal structures of biofilm will be formed. It is not clear whether rhamnolipids and the
synthetic analogs in our studies,136, 138 are just signaling molecules that trigger the
formation of pores and channels; or whether they also take part as a structural component
to build and maintain the fluid void structures in a biofilm; or, whether they also act as
anchors to which the bacteria attach in a biofilm. This subject is an ongoing area of
research in our studies.

3.3. Conclusions

In this work, we found that synthetic rhamnolipid-analogs active for controlling
swarming (inhibition and activation) also promote biofilm formation of a non-swarming
strain, rhlA mutant, at relatively low concentration, but inhibit biofilm formation at high
concentration. Agents that are inactive at controlling swarming motility are also not
active in influencing the biofilm formation of the rhlA mutant. We also find that biofilm
of PAO1 under shaking conditions exhibited porous structures, whereas under static
conditions showed relatively uniform biofilms. Using this result as criteria for
comparison between structured and nonstructured biofilms, we find that biofilm
formation caused by the presence of rhamnolipid-analogs at intermediate concentrations
also exhibited porous features. Together, these results suggest that synthetic rhamnolipidanalogs behave as signaling molecules and can substitute rhamnolipids for functional
control. Among many other approaches,157-158 chemical signaling that governs the
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quorum sensing of bacteria has been a target for developing anti-bacterial as well as
potential therapeutic agents.147, 154, 159 We believe that a new approach of developing
mimics and dominating agents of the environmental cues bears an enormous potential for
developing therapeutic agents and chemical applications.

3.4 Materials and methods

3.4.1. Synthetic procedure

Synthesis of C6OC5OH: 0.51 g (12.9 mmol) of NaH (60% dispersion in mineral
oil) was suspended in 10 mL of DMF and added to a solution of pentan-1,5-diol (2.69 g,
25.8 mmol) in DMF (6 ml). 1-bromohexane (1.33 g, 8.06 mmol) was then added drop by
drop under argon and stirred overnight. The reaction mixture was quenched with
deionized water and extracted with 1:1 hexane and ethyl acetate. Then the organic phase
was concentrated in vacuo at 35 °C. The crude product was then purified by column
chromatography. The product was obtained as colorless oil, 1.17 g, 73 %, Rf = (0.35, 45
% EtOAc in Hexane). 1H NMR (400 MHz, CDCl3): δ 3.63 (t, 2H), 3.38 (t, 2H), 3.36 (t,
2H), 1.70-1.21 (m, 14H), 0.88 (t, J= 6.3 Hz, 3H). HRMS (ESI+): Cacld. for M+:
189.1776, found: 189.1853

Synthesis of C3OC8OH: 0.51 g (12.9 mmol) of NaH (60% dispersion in mineral
oil) was suspended in 10 mL of DMF and added to a solution of octan-1,8-diol (3.77 g,
25.8 mmol) in DMF (6 ml). 1- bromopropane (0.99 g, 8.06 mmol) was then added drop
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by drop under argon and stirred overnight. The reaction mixture was quenched with
deionized water and extracted with 1:1 hexane and ethyl acetate. Then the organic phase
was concentrated in vacuo at 35 °C. The crude product was then purified by column
chromatography. C3OC8OH was obtained as colorless oil, 1.13 g, 69 %, Rf = (0.37, 45 %
EtOAc in Hexane). 1H NMR (400 MHz, CDCl3): δ 3.63 (t, 2H), 3.36 (t, 2H), 3.34 (t,
2H), 1.66-1.20 (m, 14H), 0.88 (t, J= 6.3 Hz, 3H). HRMS (ESI+): Cacld. for M+:
189.1776, found: 189.1853

Synthesis of acetylated-bromo-cellobiose: To an oven-dried round bottom flask,
cellobiose (1.0 g, 2.8 mmol), AcBr (~3.6 mL, 44.4mmol), and AcOH (19 mL) were
added and stirred at room temperature (25 °C) for ~ 1 h. The reaction mixture was
concentrated in vacuo at 35 ⁰C and then co-evaporated three times with PhMe (2×10 mL,
anhydrous). After removal of solvent, the flask was further heated in vacuo at 50 ⁰C for
15min to give a foamy solid, aceto-bromo-cellobiose. The crude aceto-bromo cellobiose
was immediately used in next step without any further purification.

Synthesis of acetylated C6OC5βC and acetylated C3OC8βC: For obtaining βanomer as the major product, the crude aceto-bromo cellobiose was dissolved in MeCN
(10 mL) and 2 equivalents of C6OC5OH (1.05 g, 5.6 mmol) or C3OC8OH (1.05 g, 5.6
mmol) were added along with two equivalents of FeCl3 (5.6 mmol). The reaction mixture
was stirred vigorously for about ~45-60 mins at rt. After stirring at rt, aq KBr (10%, 25
mL) and then toluene (60 mL) were added under stirring. The organic phase was washed
twice with aq KBr (10 %, 2×25 mL), once with aq NaHCO3 (5 %, 25 mL) and twice with
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H2O (2×25 mL). The crude product was then purified by column chromatography using
gradient elution (100 % hexane to 40 % ethyl acetate in hexane). Acetylated C6OC5βC
was obtained as Colorless powder, 0.42 g, 21.3 % (2-step), Rf = (0.36, 40 % EtOAc in
Hexane). 1H NMR (400 MHz, CDCl3): δ 5.20 (m, 3H), 4.93 (q, J1-2 = 8.4 Hz, 2H), 4.544.43 (m, 3H), 4.39 (dd, J1-3 = 12.9 Hz, J1-2 = 4.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.87- 3.74
(m, 2H), 3.69-3.56(m, 2H), 3.44 (q, 1H), 3.38 (t, 2H) 3.36 (t, 2H) 2.13-1.99 (s, 7 X 3H),
1.70-1.21 (m, 14H), 0.88 (t, J= 6.3 Hz, 3H). Acetylated C3OC8βC was obtained as
colorless powder, 0.50 g, 23.1 % (2-step), Rf = (0.42, 40 % EtOAc in Hexane). 1H NMR
(400 MHz, CDCl3): δ 5.20 (m, 3H), 4.93 (q, J1-2 = 8.4 Hz, 2H), 4.54-4.43 (m, 3H), 4.39
(dd, J1-3 = 12.9 Hz, J1-2 = 4.8 Hz, 1H), 4.13-4.02 (m, 2H), 3.87- 3.74 (m, 2H), 3.693.56(m, 2H), 3.44 (q, 1H), 3.36 (t, 2H), 3.34 (t, 2H), 1.66-1.20 (m, 14H), 0.88 (t, J= 6.3
Hz, 3H).

Synthesis of C6OC5βC and C3OC8βC: The deprotection of acetyl groups was
achieved by Zemplén deacetylation using MeONa/MeOH (10 mM solution) conditions
followed by neutralization (pH ~6.5) over H+ amberlite resins. The resins were filtered
off and products dried under high vacuum overnight. C6OC5βC was obtained as colorless
powder, 0.23 g, 87 %. 1H NMR (300 MHz, CD3OD): δ 4.36 (d, J = 7.8 Hz, 1H), 4.28 (d,
J = 7.8 Hz, 1H), 3.82 (m, 4H), 3.69-3.47 (m, 4H), 3.40-3.25(m, 8H, overlapping with
MeOH), 3.18-3.11 (m, 2H), 1.60-1.13 (m, 14H), 0.82 (t, J= 6.3 Hz, 3H). 13C NMR (100
MHz, CD3OD): δ 103.2, 102.8, 79.3, 76.7, 76.4, 75.1, 75.0, 73.7, 73.5, 70.7, 70.4, 69.9,
69.3, 61.4, 60.5, 31.4, 29.3, 29.2, 29.1, 25.5, 22.3, 22.1, 13.0. HRMS (ESI) m/z: Calcd.
(C23H44O12)Na+: 535.2731; Found: 535.2728. C3OC8βC was obtained as colorless
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powder, 0.24 g, 91 %. 1H NMR (300 MHz, CD3OD): δ 4.33 (d, J = 7.8 Hz, 1H), 4.19 (d,
J = 7.8 Hz, 1H), 3.78 (m, 4H), 3.63-3.39 (m, 4H), 3.40-3.25(m, 8H, overlapping with
MeOH) 1.66-1.20 (m, 14H), 0.85 (t, J= 6.3 Hz, 3H). 13C NMR (100 MHz, CD3OD): δ
103.2, 102.8, 79.3, 76.7, 76.4, 75.1, 75.0, 73.7, 73.4, 72.1, 70.4, 69.9, 69.3, 61.4, 60.5,
29.3, 29.3, 29.1, 29.1, 25.8, 25.6, 22.5, 9.5. HRMS (ESI) m/z: Calcd. (C23H44O12)Na+:
535.2731; Found: 535.2728.
3.4.2. Bacterial strains

Wild-type P. aeruginosa PAO1 and PAO1-EGFP strains were obtained from Dr.
Guirong Wang (Upstate Medical University, Syracuse). The non-swarming mutant of P.
aeruginosa, rhlA (PW6886, rhlA-E08::ISphoA/hah) was obtained from PA two-allele
library (PAO1 transposon mutant library).156
3.4.3. Crystal violet dye-based biofilm inhibition assay

Inhibitory effect of all the maltose hydrocarbons on the biofilm formation by rhlA
mutant was determined by crystal violet dye based biofilm inhibition assays. An
overnight culture of the rhlA mutant was subcultured to an OD600 of 0.01 into the LB
medium. 200 µL of the subculture was aliquoted into the wells of 96-well polystyrene
microtiter plate when it reached the OD600 of 0.1. Predetermined concentrations of the
test compounds were then added to the respective wells containing subculture. Sample
plates were wrapped in GLAD Press n’ Seal® followed by incubation under stationary
conditions for 24 h at 37 °C. After incubation, the media was discarded and the plates
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were washed with water and dried for 1 h at 37 °C. The sample plates were stained with
200 μL of 0.1% aqueous solution of crystal violet (CV) and followed by incubation at
ambient temperature for 20 min. The CV stain was then discarded and the plates were
washed with water. The remaining biofilm adhered stain was re-solubilized with 200 μL
of 30 % acetic acid. After the stain was dissolved (15 minutes), 100 μL of the solubilized
CV was transferred from each well into the corresponding wells of a new polystyrene
microtiter dish. Biofilm inhibition was quantified by measuring the OD600 of each well in
which a negative control lane wherein no biofilm was formed served as a background and
was subtracted out. The percent inhibition was calculated by the comparison of the OD600
for biofilm grown in the absence of compound (control) versus biofilm grown in the
presence of compound under identical conditions. Biofilm inhibition assay with all the
maltose derivatives was repeated four times and each data point in the graph is the
average of values from 6 wells.

3.4.4. Confocal laser scanning microscopy (CLSM)

Biofilms were grown by inoculating the bacteria on polystyrene coupons (3/8 in.
× 3/8 in.) with or without rhamnolipid analogs in a 24-well microtiter plate. The saranwrapped plate was then incubated at 37 oC with or without shaking. Each polystyrene
coupon was then washed gently by dipping into 0.85 w/v% aqueous NaCl solutions twice
and then placed on a microscope cover glass (50 x 24mm, No. 2, Fisher Scientific,
Pittsburgh, PA). The biofilms were visualized using a Zeiss LSM 710 Confocal Laser
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Scanning Microscope (Carl Zeiss, Jena, Germany). A 488 nm laser line was used to
visualize biofilms formed by PAO1-EGFP and rhlA-EGFP strains.
3.4.5. Biofilm inhibition assay

An overnight culture of rhlA strain was subcultured to an OD600 of 0.01 in the LB
medium. 200 µL of the subculture was aliquoted into the wells of 96-well polystyrene
microtiter plate when it reached the OD600 of 0.1. The stock solutions of the test
compounds in sterile water were added to the wells containing the subculture to achieve
the predetermined concentrations. Sample plates were wrapped in polyvinylidene
chloride (PVDC) and incubated without shaking for 24 h at 37 °C. After incubation, the
media was discarded and the plates were washed with water and dried for 1 h at 37 °C.
200 µL of LB media and the test compounds were then added to the corresponding wells
again. Sample plates were wrapped in PVDC and incubated without shaking for another 1
h at 37 °C. 100 μL of the media from each well was transferred into the corresponding
wells of a new polystyrene microtiter plate. And the OD600 of each well was read by a
microplate reader Elx800 (BIO-TEK Instruments, Inc., Winooski, VT, USA). A control
lane containing pure LB media served as a background and was subtracted out. The
percent bacteria in the biofilm was calculated by the comparison of the OD600 for bacteria
grown in the absence of compound (control) versus bacteria grown in the presence of
compound under identical conditions. Each data point in the graph is the average of
values from 6 wells.
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HRMS Spectra

HRMS (ESI+): Cacld. for M+: 189.1776, found: 189.1853

HRMS (ESI+): Cacld. for M+: 189.1776, found: 189.1853

HRMS (ESI) m/z: Calcd. (C23H44O12)Na+: 535.2731; Found: 535.2728.
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HRMS (ESI) m/z: Calcd. (C23H44O12)Na+: 535.2731; Found: 535.27
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Chapter 4 Synthetic Disaccharide Derivatives Inhibit Bacterial Antibiotic-Promoted
Activities and Increase the Potency of Antibiotics to Remove Biofilms*
4.1. Introduction
4.1.1. A brief introduction of antibiotic resistance, tolerance, and persister

Antibiotic-treatment failure is typically attributed to antibiotic resistance.77, 160
“Resistance” is used to describe the inherited ability of microorganisms to grow at high
concentrations of an antibiotic, and can be quantified by the minimum inhibitory
concentration (MIC) of the particular antibiotic,161 Resistance is most often thought of as
being attributable to mutations or exchange of antibiotic resistance genetic elements,
although resistance may also be intrinsic and thus dependent on wild-type genes and
innate properties of the cell.162-163 For example, Gram-negative bacteria are intrinsically
more resistant than Gram-positive cells to certain antibiotics like vancomycin due to the
relatively less outer membrane permeability. Resistance mechanisms have been described
by Lewis164 as the means by which an antimicrobial agent is prevented from interacting
with its intended target including antibiotic efflux pumps,165 molecules (such as eDNA166
and NdvB-derived periplasmic glucans167) that sequester antibiotics, and matrix βlactamases168.
In contrast, “tolerance”, which is defined by Kester and Fortune, is used to
describe the ability of microorganisms to survive transient exposure to high
concentrations of an antibiotic without a change in the MIC, which is often achieved by

*

The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and
13
CNMR collected by Felicia Burns were included for the purpose of completing the information.
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slowing down an essential bacterial process.169-170 In the presence of the antibiotic,
tolerant bacteria cease to grow; however, they can start to grow and replicate once the
antibiotic is removed.171 Tolerance is an inherited rather than a non-inherited form of
antibiotic resistance; tolerant cells are genetically different to the non-tolerant bacteria
from which they are derived.172-175 A measure of tolerance is the minimum bactericidal
concentration (MBC), which is the lowest concentration of a bactericidal antimicrobial
that will kill ≥99.9% of cells in a culture.176 Mechanisms of tolerance are thought to
somehow prevent the bactericidal agent from exerting its downstream toxic effects even
though the agent has bound to its target.164 Based on this definition, antibiotic tolerance
mechanisms include reduced growth rate177-178, the mechanisms that handle antibioticinduced oxidative stress179 and persister cells180.
In contrast to resistance and tolerance, which are attributes of whole bacterial
populations, ‘persistence’ is a term that describes the ability of a subpopulation of a
clonal bacterial population to survive exposure to high concentrations of an antibiotic.181
Persistence, was first reported for staphylococcal infections treated with penicillin and
has since been observed in many bacterial species.182 Despite being observed almost for
decades, the mechanism behind persistence remains a puzzle. The reason might due to
technical difficulties of working with a small fraction of cells expressing a temporary
phenotype of uncertain functional significance.183-184 In the 1980s, Harris and coworkers
continued working on to search for genes that caused persister formation.185-188 One of
these persister mutations was mapped to the hipA gene. The hipA7 allelic strain produced
~1% persisters that survived treatment with ampicillin in exponential cultures, which is
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approximately 1,000 times more persisters than the wild-type strain. The recent discovery
of persisters in biofilms has led to a great interest in studying those unusual cells.180, 189
Bacteria have the potential to adapt to the environment, either under natural or
laboratory condition.190 Recent studies have shown that tolerance and persistence evolve
rapidly under intermittent antibiotic exposure. Nathalie and coworkers reported resistance
enhancement in bacterial populations under cyclic antibiotic treatments.191 Maarten and
Jan demonstrated that persistence is a highly evolvable trait that quickly adapts to drugtreatment frequency,192 and that its evolutionary dynamics can be understood in the
context of bet-hedging theory.193-197 Hinrich and Gunther reported that P. aeruginosa
adapts rapidly to high-level antibiotic stress and they expressed both collateral sensitivity
and cross-resistance which was revealed by genomic and functional genetic analysis.198
Evolution of resistance from tolerance indicates that new drugs or their combinations that
decrease tolerance may intervene in the resistance evolution process.
4.1.2. The effect of sub-MIC antibiotics on P. aeruginosa biofilm formation
Pseudomonas aeruginosa forms biofilm with extreme tolerance to antibiotics in
nosocomial infections, such as pneumonia and surgical site infections. The Diseases
Society of America declared Pseudomonas aeruginosa is one of the six ‘top-priority
dangerous, drug-resistant microbes.199 More than 60% of the bacterial infections
currently treated by physicians are considered to involve biofilm formation.128 Successful
treatment in these cases depends on the effective removal of those biofilm materials.
Since the discovery of penicillin, antibiotics have been proven to be effective in
controlling serious bacterial infections.63 Microbiologists have been using minimal
inhibitory concentration (MIC) and the minimal bactericidal concentration (MBC) to
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assess the effect of antibiotics against planktonic organisms. Table 4.1 showed MIC and
MBC of 6 different antibiotics toward P. aeruginosa. As mentioned in chapter 1,
antibiotics can act as signaling molecules that trigger transcription responses important
for environmental survival in low concentrations.75-76 While the growth of surrounding
microorganisms could be inhibited at high concentrations of antibiotics are present.77
Various studies have shown that sub-minimal inhibitory (sub-MIC) concentrations of
some antibiotics can inhibit biofilm formation without killing the bacteria. Ichimiya and
coworkers found that azithromycin can efficiently inhibit Pseudomonas aeruginosa
biofilm formation at 1/128 of the MIC.200-201 Low dose azithromycin therapy has been
shown to improve lung function in cystic fibrosis patients.202-204 The effect of low-dose
azithromycin chemotherapy may be due to its ability to inhibit quorum sensing and
alginate production of mucoid biofilms at sub-MIC concentrations.205-207
Table 4.1 MIC and MEC of different antibiotics for P. aeruginosa

MIC
(mg/L)

MBC
(mg/L)

Primary target

Antibiotic
Aztreonam

2208/16209

-

Penicillin-binding proteins

Chloramphenicol

-

1024210

50S ribosome (Protein translation)

Tetracycline

-

512211

30S ribosome (Protein translation)

Ciprofloxacin

1212

4213

Topoisomerase II (DNA gyrase),
topoisomerase IV

Colistin

8~16214

64~128214

Cell membrane

Tobramycin

1215

~53210

30S ribosome (Protein translation)
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However, there are numerous studies have shown that some antibiotics can induce
biofilm formed by P. aeruginosa when present at concentrations below the MIC. Garey and
coworkers216 showed that sub-MIC concentrations of clarithromycin induced biofilm
formation by 25-fold in 44 P. aeruginosa clinical isolates when tested at 1/32 to 1/2 MIC.
Linares and coworkers217 found that sub-MIC concentrations of tobramycin, ciprofloxacin,
and tetracycline-induced P. aeruginosa biofilm formation by approximately 2-fold. Bagge
and coworkers218 also used microarray technology to study the effects of sub-MIC
concentrations of the β-lactam antibiotic imipenem on P. aeruginosa biofilm formation.
They identified 34 genes that were induced or repressed in biofilms exposed to 1/2 MIC
imipenem. Five alginate metabolism-related genes (algD, algG, algJ, algF, and algA) were
induced more than 10-fold by imipenem at 1/2 MIC. Hoffman and coworkers42 found that
sub-MIC concentrations of tobramycin readily induced P. aeruginosa biofilm formation
while several other antibiotics including polymyxin B, chloramphenicol and carbenicillin
had no effect on biofilm formation.42 They found that all the mutants carried transposon
insertions in a gene designated arr, which is an aminoglycoside response regulator that
encodes a c-di-GMP phosphodiesterase that degrades c-di-GMP and reduces intracellular
c-di-GMP concentrations, were defective in tobramycin-induced biofilm formation.42 The
results suggested that Aminoglycoside antibiotics such as tobramycin could act as first
messengers that trigger changes—mediated either by binding directly to proteins such as
Arr or indirectly through intermediary molecules—in the level of the second messenger cdi-GMP.42

75

4.1.3. Puzzle: Biofilm formation and swarming motility are inversely regulated but both
activities can be induced by antibiotics

Switching between sessile and motile states is an important decision for the
bacteria to ensure its survival.48 However, external environmental stimuli that cause the
transition from sessile to motile mode still remains unclear.48, 219-220 As both swarming
and biofilm formation are surface-associated multicellular behaviors that are controlled
by bacterial quorum sensing, it is important to understand the relation between the two
behaviors. SadB was originally identified as required for early biofilm formation, is also
a negative effector of swarming motility. O’Toole and co-workers found that sadB gene
of P. aeruginosa is most likely responsible for inversely regulating the swarming and
biofilm formation through the chemotaxis cluster IV.221-222 The authors also proposed that
P. aeruginosa inversely regulates the surface-associated behaviors of biofilm formation
and swarming by controlling both flagellar reversals and the production of the Pel
polysaccharide. It has been observed that during the biofilm formation process bacterial
cells were switched from one lifestyle to another to adapt to the new lifestyle.223 For
instance, during the biofilm formation process the cells of P. aeruginosa usually develop
single polar flagella to assist the surface adherence process, while during swarming, P.
aeruginosa seems to develop two polar flagella.43, 219
There are numerous studies have shown that antibiotics not only induce biofilm
formation it can also induce swarming motility of P. aeruginosa when present at
concentrations below the MIC. Hoffman and coworkers42 found that sub-MIC
concentrations of tobramycin readily induced P. aeruginosa biofilm formation. Garey and
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coworkers216 showed that sub-MIC concentrations of clarithromycin induced biofilm
formation by 25-fold in 44 P. aeruginosa clinical isolates when tested at 1/32 to 1/2 MIC.
Linares and coworkers found that sub-MIC of tobramycin increased bacterial swarming
motility.217 However, the mechanism of antibiotics inducing P. aeruginosa biofilm
formation and swarming motility is still unclear.

4.1.4. The aim of the chapter

In this chapter, we have examined the effect of our synthetic disaccharide
derivatives on sub-MIC antibiotic-promoted biofilm formation and swarming motility.
The preliminary investigation by our previous lab members brought forward the
hydrocarbon maltoside and cellobioside derivatives as potent biofilm and swarming
inhibitors. Additionally, the fact that many saccharide-hydrocarbons are involved in
bacterial surface recognition events further prompted us to explore the effect of our
synthetic SFβM along with other potent leads 3,5-DMDβM and 3,5-DMDβC on sub-MIC
antibiotic-promoted biofilm formation and swarming motility. Furthermore, we have
examined the efficacy of two compounds SFβM and SF(EG)4OH in enhancing the
bactericidal action of antibiotics colistin and tobramycin on biofilms grown on a
polystyrene surface. In addition, to study drug tolerance and persister formation, we
examined the ability of our molecules to eradicate drug tolerance and persisters induced
by the presence of antibiotics using resazurin dye-based cell viability assay. To study the
effect of our synthetic molecules, 3,5-DMDβM and 3,5-DMDβC, on the efficacy of
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antibiotics to combat tobramycin-tolerant subpopulations, we examined the live and dead
subpopulation of native and tobramycin promoted biofilms by confocal laser scanning
microscope (CLSM).

4.2. Results and discussion
4.2.1. Library of molecules used in this study
In order to investigate the effect of our synthetic molecules on inhibiting
antibiotic-promoted bacterial activities and increase the potency of antibiotics to kill
bacteria in biofilms, a library of molecules was tested which has been listed in Figure 4.1.
2-ABI is a commercially available molecule. SF(EG)4OH and SFβM were designed and
synthesized by our previous lab member Nischal. 3,5-DMDβM and 3,5-DMDβC were
designed and synthesized by our current lab member Felicia Burns.
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Figure 4.1 Collection of molecules used in this study. 3,5-DMDβM and 3,5-DMDβC are
synthesized and characterized by Felicia Burns.

4.2.2. Disaccharide molecules having branched hydrocarbons inhibit tobramycinpromoted bacterial activities
Biofilm formation and swarming motility are two critical pathogen-related
functions of bacteria.221 Below the lethal concentration, tobramycin promotes both
bioactivities by P. aeruginosa.100 In contrast, our potent lead compound, SFβM, inhibit
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both biofilm formation and swarming motility. The mechanism for these observations is
not yet clear, but we have identified two proteins to which SFβM binds: Lectin A and pilin,
which I will describe in detail in chapter 5 and 6. Here, we examined the influence of
synthetic disaccharide derivatives supplemented with Las quorum sensing inhibitor ABI
on normal biofilm and sub-MIC of tobramycin promoted biofilm formed by PAO1-EGFP
strain under slow shaking condition (100 rpm). Biofilm inhibition activity of active
disaccharide derivatives was verified by fluorescence-based biofilm assay. P. aeruginosa
strain, PAO1-EGFP that constitutively expresses a green fluorescent protein (GFP) was
allowed to grow on sterile polystyrene coupons for 24 h. The biofilms formed on the
coupons grown in the presence and in absence of maltose derivatives were viewed under
confocal laser scanning microscope (CLSM). The fluorescence observed indirectly
indicates the amount of biofilm formed on the coupons. The biomass of biofilm was
quantified using COMSTAT software. At 24 h, there is visibly less fluorescence signal for
biofilm formed by the PAO1-EGFP strain which was treated with 40 µM SFβM/ABI, than
biofilm formed without any added agents (Figure 4.2). For the sub-MIC of tobramycin
promoted biofilm, there is visibly more fluorescence signal compared to biofilm formed
without any added agents (Figure 4.2). In addition, adding 40 µM SFβM/ABI along with
0.3 µg/mL tobramycin, biofilms formed significantly less than sub-MIC of tobramycin
promoted biofilm based on fluorescence signals. These results suggest that SFβM not only
inhibited normal biofilm formed by PAO1-EGFP it also inhibited sub-MIC of tobramycin
promoted biofilm. However, the remained portion of sub-MIC of tobramycin promoted
biofilm after grown with 40 µM SFβM is still more than the remaining portion of 40 µM
SFβM/ABI treated normal biofilm formed by PAO1-EGFP.
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B

+ 40
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SFβM/
ABI
D
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Figure 4.2 Representative confocal laser scanning microscopy (CLSM) micrographs of
biofilm formed by PAO1-EGFP without (A) and with (B) Tobramycin (Tob) at a sub-MIC
(0.3 μg/mL). Adjuvant molecules SFβM & 2-amino benzimidazole (2-ABI) (40 µM each)
inhibit both native (C) and tobramycin-promoted biofilm (D). Biofilms were grown on
polystyrene for 24 h with shaking (100 rpm). Scale bar = 30 μm. The thickness and biomass
of biofilm were quantified using COMSTAT software.
Furthermore, the CLSM images show that the biofilm formed on the coupons in
presence of 3,5-DMDβM and 3,5-DMDβC were significantly lower than those formed
without agents (Figure 4.3). In the presence of 0.3 µg/mL tobramycin, which is the optimal
condition for forming a sub-MIC antibiotic-promoted biofilm, the thickness was increased
around 30%. When adding disaccharide derivatives, 3,5-DMDβM and 3,5-DMDβC, the
thickness of the sub-MIC antibiotic-promoted biofilm were significantly decreased by
around 50%.
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Figure 4.3 Representative confocal laser scanning microscopy (CLSM) micrographs of
biofilm formed by PAO1-EGFP on polystyrene coupons; biofilms on the first row were
grown in the absence of agents(control), and in the presence of 85 μM 3,5-DMDβM and
3,5-DMDβC. * Biofilms on the second row were grown under the same condition as the
first row plus 0.3 µg/mL Tobramycin. Bacterial strain: PAO1-EGFP; Initial OD600:
0.01; Surface: Polystyrene; Time: 24 h; Shaking speed: 100 rpm; Scale bar: 30 µm. The
thickness and biomass of biofilm was quantified using COMSTAT software.

*

The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and
13
CNMR collected by Felicia Burns were included for the purpose of completing the information.
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In addition, we examined the eradication effect of SFβM and amino
benzimidazole on preformed native and tobramycin promoted biofilms. Specifically, we
first grow a biofilm of PAO1-EGFP strain with and without 0.3 µg/mL of tobramycin for
24 h to establish an antibiotic-promoted biofilm and a native biofilm, respectively. For
each biofilm, we then introduced fresh LB medium with and without 40 µM of SFβM or
40 µM 2-ABI or both. The thickness and biomass of biofilm were quantified using
COMSTAT software. The results showed that during this second culture period, around
30-40 % of native biofilm was eradicated when 40 µM of SFβM was added. The biofilm
thickness was decreased ~25% as well. However, 40 µM 2-ABI did not have any
significant effect on either biofilm thickness or the biomass. Furthermore, the effect of
adding both 40 µM of SFβM and 40 µM 2-ABI is similar to adding 40 µM of SFβM
alone (Figure 4.4).
Eradication effect of SFβM and amino benzimidazole on preformed tobramycin
promoted biofilms was tested using the similar way above. The results showed that
during this second culture period, around 25 % of tobramycin promoted biofilm was
eradicated when 40 µM of SFβM was added. However, the biofilm thickness was only
decreased by ~10 %. 40 µM 2-ABI did not have any significant effect on either biofilm
thickness or the biomass. Furthermore, the effect of adding both 40 µM of SFβM and 40
µM 2-ABI is similar to adding 40 µM of SFβM alone (Figure 4.5). The reason why
antibiotic-promoted biofilms were slightly more difficult to eradicate than native biofilms
is probably due to certain exopolymer acting as physical barriers and reduce the
penetration of antibiotic into the deep part of biofilms, which allows more biofilm cells to
survive and acquire tolerance.214
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Figure 4.4 Representative confocal laser scanning microscopy (CLSM) micrographs of
biofilm formed by PAO1-EGFP. Adjuvant molecules SFβM & amino benzimidazole
(ABI) (40 µM each) inhibit native biofilm formation. Biofilms were grown on
polystyrene for 24 h with shaking (100 rpm). Scale bar = 30 μm. The thickness and
biomass of biofilm were quantified using COMSTAT software.
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Figure 4.5 Representative confocal laser scanning microscopy (CLSM) micrographs of
biofilm formed by PAO1-EGFP with Tobramycin (Tob) at a sub-MIC (0.3 μg/mL).
Adjuvant molecules SFβM & amino benzimidazole (ABI) (40 µM each) inhibit
tobramycin-promoted biofilm formation. Biofilms were grown on polystyrene for 24 h
with shaking (100 rpm). Scale bar = 30 μm. The thickness and biomass of biofilm were
quantified using COMSTAT software.

Swarming is a complex mode of translocation that is fundamentally different from
other bacterial motilities like swimming and twitching. It has been reported that P.
aeruginosa requires all of the following features to successfully swarm on a semisolid
surface; quorum sensing, flagella, pili and production of biosurfactant rhamnolipids.219
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PAO1 strain used in this study grows outward from the point of inoculation without
forming any tendril patterns. Here, we examined the influence of synthetic disaccharide
derivatives on normal and sub-MIC of tobramycin promoted swarming of PAO1 strain. It
is evident from the images of swarm agar plates that the area or the diameter of PAO1
added with 20 µM SFβM was significantly smaller than PAO1 control without adding
any agents (Figure 4.6). However, when adding 0.3 µg/mL of tobramycin, the swam area
is slightly bigger than PAO1 control without adding any agents which indicate that the
swarming of PAO1 is promoted by tobramycin. Furthermore, adding 20 µM SFβM along
with 0.3 µg/mL of tobramycin significantly inhibits swarming of PAO1(Figure 4.6).
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Figure 4.6 Swarming of PAO1 (A) is promoted by tobramycin (0.3 µg/mL) (B). Adding
20 µM SFβM to the swarm plates inhibits swarming without (C) and with (D) added
tobramycin.
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4.2.3. Synthetic agents acting as adjuvant compounds to enhance the activity of
antibiotics against bacteria in biofilms on an abiotic surface

We also assessed the ability of our compounds to facilitate the killing of preformed biofilms in our co-culture model of PA biofilms on polystyrene surfaces. Here,
we tested two antibiotics, colistin, and tobramycin, which were proven to be most
effective against PA bacteria (see Figure 4.7). In this assay, biofilms were grown on
polystyrene surfaces for 24 h to reach the mature state. Then predetermined
concentrations of antibiotics (25 µg/mL, 30 µg/mL, 35 µg/mL colistin and 8 µg/mL, 16
µg/mL, 32 µg/mL tobramycin) and agents (50 µM SFβM and 50 µM SF(EG)4OH) were
added to those pre-formed biofilms and incubated for another 24 h. Survived bacteria
were quantified by OD600 readings. For colistin, added synthetic agents significantly
enhanced the efficacy of the antibiotics. When SFβM or SF(EG)4OH were added to 25
µg/mL and 35 µg/mL colistin, the survived bacteria within the biofilms were decreased
by 75-85 % (Figure 4.8). However, the efficacy of SFβM or SF(EG)4OH in enhancing the
action of tobramycin is not as good as colistin. The results showed the efficacy of two
compounds in enhancing the action of colistin versus biofilms grown on a plastic surface,
and modest enhancement of tobramycin (Figure 4.8).
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Figure 4.7 Adjuvant compounds enhance the activity of antibiotics versus biofilms on an
abiotic surface. Shown is the impact of adjuvant compounds in combination with five
antibiotics for a biofilm grown on an abiotic (polystyrene) surface.
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Figure 4.8 Adjuvant compounds enhance the activity of antibiotics versus biofilms on an
abiotic surface. Shown is the impact of two different adjuvant compounds in
combination with colistin (A) and tobramycin (B) for a biofilm grown on an abiotic
(polystyrene) surface. Addition of either compound markedly enhances the % killing (Yaxis) of colistin.

Our molecules enable tobramycin to eradicate the drug-tolerant bacteria and
nascent persisters often generated by treatment with this antibiotic. Thus, we have
discovered a class of adjuvant agents for controlling antibiotic-induced problems of
tolerance, induced persisters, and potentially, fully-developed resistance. To study drug
tolerance and persister formation, we first grow a biofilm of PA strain PAO1 (a typical
laboratory strain) on pegs224 with and without 0.3 µg/mL of tobramycin for 24 h to establish
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an antibiotic-promoted biofilm, which contains both drug-tolerant bacteria and nascent
induced persisters, and a native biofilm, respectively. For each biofilm, we then introduced
a fresh medium containing a high concentration of tobramycin (50 µg/mL) with and
without 40 µM of SFβM +/- 40 µM ABI. During this second culture period with a high
dose of tobramycin, we evaluate the effect of our molecules on tobramycin’s killing of
bacteria in biofilms as a function of time up to 24 h. Figure 4.9 shows that during the first
10-h versus a control biofilm, our molecules have a small, non-significant impact on
tobramycin-mediated killing; no such enhancement is observed beyond 10 hrs (Figure
4.9.A). In contrast, for the tobramycin (0.3 µg/mL)-promoted biofilm,100 we make three
observations (Figure 4.9.B). First, without our molecules, a slower rate of killing was
observed from the 2nd hour to the 12th hour when this biofilm was treated with tobramycin
(50 µg/mL; Figure 4.9.B, bracket labeled “a”). This result is consistent with the existence
of tobramycin-tolerant bacteria. Second, our molecules (SFβM/ABI) enabled the high dose
of tobramycin (50 µg/mL) to kill tolerant bacteria that developed during the first 24-h
culture with low antibiotic concentration (Figure 4.9.B, bracket labeled “b”). Third, for
both control (“native”) and tobramycin-induced biofilms, a plateau of killing was observed
beyond ~12 h, but a higher resazurin dye signal (i.e., live bacteria)225-226 is observed for the
biofilm without our molecules compared to with SFβM/ABI (Figure 4.9.B). We confirmed
that at the end of the high dose tobramycin treatment (50 µg/mL), viable bacteria could be
detected in both treatments (with and without our agents). This result indicates that the
existence of persisters in both biofilms (but with different amounts) for the last 12-h of
high dose tobramycin treatment. To further confirm that these bacteria were persisters, we
collected large amount of these bacteria (from 20 pegs when plateaus were reached),
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sonicated them in saline water (to prevent phenotype reversion), concentrated to get the
pellet, and cultured the pellet again in LB containing 10 µg/mL of tobramycin, and in fresh
LB. Whereas there was no growth observed in LB containing 10 µg/mL tobramycin,
bacteria from this treatment always regrow in fresh medium. Together, these finding and
data from Figure 4.9.B suggest that our molecules enable tobramycin to kill and/or to
prevent a portion of persisters in the drug-treated bacterial population.
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Figure 4.9 The fluorescence of resazurin dye showing live PA strain PAO1 in (A) native
and (B) tobramycin (Tob, 0.3 µg/mL)-promoted biofilms, which were treated with 50
µg/mL Tob, and with (solid line) and without (dash line) 40 µM (~22 µg/mL) SFβM &
40 µM ABI at different times. Interpretation of panel B: “a” consists of susceptible and
tolerant bacteria, plus persisters; “b”, susceptible bacteria, plus persisters; “c”,
tobramycin -induced persisters.
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4.2.4. Adjuvant compounds enhance the efficacy of antibiotics to combat tobramycintolerant subpopulations

To study the effect of adjuvant compounds on the efficacy of antibiotics to
combat tobramycin-tolerant subpopulations, we first grow biofilms of PAO1 on
polystyrene chips with and without 0.3 µg/mL of tobramycin for 24 h to establish native
and antibiotic-promoted biofilms. In the next 24 h, we increased the concentration of
tobramycin to 50 µg/mL with and without 85 µM 3,5-DMDβM or 3,5-DMDβC, and then
we monitored the development of live and dead subpopulations of P. aeruginosa biofilms
by confocal image acquisition. A 488 nm laser line was used to visualize live cells within
the biofilms formed by PAO1-EGFP strain. Dead cells within the biofilm stained by
propidium iodide were visualized by 635 nm laser line. The image analysis program
COMSTAT was used to analyze images stained with the LIVE/DEAD viability stain by
recognizing the relative biomass that fluoresces green (live) and red (dead) at levels
above a user-defined threshold value and reports the percentage of biomass that is alive
and the percentage of biomass that is dead in each slice in a stack of images. The areas of
the biomass fluorescing green and red represented the relative amounts of living and dead
biomass in a biofilm.
50 µg/mL tobramycin exposure to native biofilms led to a reduction in live cell
biomass by ~50 %, and exposure to antibiotic-promoted biofilms led to a reduction in live
cell biomass by ~40 % (Figure 4.10). We also examine the effect of the combination
treatments with 85 µM 3,5-DMDβM or 3,5-DMDβC and tobramycin on native and
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antibiotic-promoted biofilms. The results showed that the combination treatments lead to
drastic change in live and dead cell subpopulation (Figure 4.10). 24 h of 50 µg/mL
tobramycin exposure combined with 85 µM 3,5-DMDβM or 3,5-DMDβC to native
biofilms caused live cell biomass further decreased by 50 % compared to when treated with
50 µg/mL tobramycin alone (Figure 4.10). However, adding 85 µM 3,5-DMDβM or 3,5DMDβC in combine with 50 µg/mL tobramycin to the native biofilms caused a significant
increase in dead cell biomass. There are 9 to 10 times more dead cells remained within the
native biofilms after 24 h of 50 µg/mL tobramycin exposure combined with 85 µM 3,5DMDβM or 3,5-DMDβC compared to when treated with 50 µg/mL tobramycin alone
(Figure 4.10).
Similarly, the combination treatments with 85 µM 3,5-DMDβM or 3,5-DMDβC
and tobramycin on antibiotic-promoted biofilms lead to drastic change in live and dead cell
subpopulation as well (Figure 4.11). 24 h of 50 µg/mL tobramycin exposure combined
with 85 µM 3,5-DMDβM or 3,5-DMDβC to antibiotic-promoted biofilms caused live cell
biomass further decreased by 70 % compared to when treated with 50 µg/mL tobramycin
alone (Figure 4.11). Dead cell biomass was significantly increased as well. There are 8 to
12 times more dead cells remained within the antibiotic-promoted biofilms after 24 h of 50
µg/mL tobramycin exposure combined with 85 µM 3,5-DMDβM or 3,5-DMDβC
compared to when treated with 50 µg/mL tobramycin alone (Figure 4.11).

93

A

Biomass (µm3/µm2)

B

15

live

dead

10
5
0

50 ug/mL Tob

50 ug/mL Tob & 85 50 ug/mL Tob & 85
µM 3,5-DMDβM
µM 3,5-DMDβC

*

Figure 4.10 Confocal microscopy images of 2-day old native biofilms. Biofilms attached
to polystyrene chips were stained using the LIVE/DEAD biofilm viability stain (A). The
images are Z-stack projections indicating the thickness of the biofilms for strain PAO1EGFP. Experiments were performed in triplicate, and a representative image for each
condition is shown. Scale bar: 30 µm. The live and dead cell biomass of biofilm
quantified using COMSTAT software (B).

*

The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and
13
CNMR collected by Felicia Burns were included for the purpose of completing the information.
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Figure 4.11 Confocal microscopy images of 2-day old antibiotic promoted biofilms.
Biofilms attached to polystyrene chips were stained using the LIVE/DEAD biofilm
viability stain(A). The images are Z-stack projections indicating the thickness of the
biofilms for strain PAO1-EGFP. Experiments were performed in triplicate, and a
representative image for each condition is shown. Scale bar: 30 µm. The live and dead
cell biomass of biofilm quantified using COMSTAT software (B).

*

The work in this chapter is a collaboration with Felicia Burns in Luk group. She synthesized and
characterized the two molecules, 3,5-DMDβM and 3,5-DMDβC, used in this chapter. 1HNMR and
13
CNMR collected by Felicia Burns were included for the purpose of completing the information.
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4.3. Conclusion
In this chapter, we confirmed that our molecule, SFβM, inhibited both tobramycinpromoted biofilm formation and swarming motility, and thus SFβM overcomes the impact
of tobramycin at controlling these two activities. 3,5-DMDβM and 3,5-DMDβC showed a
similar effect on inhibiting both tobramycin-promoted biofilm formation and swarming
motility. Thus, we can conclude that disaccharide molecules having branched
hydrocarbons inhibit tobramycin-promoted bacterial activities. SFβM and SF(EG)4OH
enhanced the bactericidal action of antibiotics colistin and tobramycin on biofilms grown
on a polystyrene surface. In addition, SFβM/ABI enabled tobramycin to kill and to prevent
a portion of persisters in the drug-treated bacterial population. Confocal microscopy study
revealed that our synthetic molecules, 3,5-DMDβM and 3,5-DMDβC, can act as adjuvant
compounds to enhance the efficacy of antibiotics to combat tobramycin-tolerant
subpopulations. Thus, supplementing conventional antibiotic treatment with an adjuvant
compound seems to be a promising therapy for eradicating biofilm-associated infections.
Furthermore, our study showed that co-treatment of adjuvant compounds along with
antibiotics is important to kill antibiotic-tolerant cells and prevent new persisters to form.
It highlighted the importance of developing motility inhibitors that can be given to
chronically infected patients, with the aim of constituting functional anti-biofilm
chemotherapies.

4.4. Materials and Methods
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4.4.1. Stock solutions

Stock solutions of all the agents were prepared in autoclaved water, sterilized by
filtering through a 0.2 µm syringe filter, and stored at -20 °C in sealed vials. An
appropriate amount of sterile water was added to controls in all assays to eliminate the
solvent effect.
4.4.2. Bacterial strains

Wild-type P. aeruginosa PAO1 and PAO1-EGFP strains were obtained from Dr.
Guirong Wang (Upstate Medical University, Syracuse). library (PAO1 transposon mutant
library).156

4.4.3. Confocal laser scanning microscopy (CLSM)

Biofilms were grown by inoculating the bacteria on polystyrene coupons (3/8 in.
× 3/8 in.) with or without agents in a 24-well microtiter plate. The saran-wrapped plate
was then incubated at 37 oC under 100 rpm shaking condition for 24 h. Inhibition of
biofilm formation was directly observed. Eradication of preformed biofilm was
performed after bacterial cultures were gently pipetted out and wells were washed, and
fresh media was added containing predetermined concentrations of antibiotics and
synthetic agents for another 24 h. Each polystyrene coupon was then washed gently by
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dipping into 0.85 w/v% aqueous NaCl solutions twice and then placed on a microscope
cover glass (50 x 24mm, No. 2, Fisher Scientific, Pittsburgh, PA). The biofilms were
visualized using a Zeiss LSM 710 Confocal Laser Scanning Microscope (Carl Zeiss,
Jena, Germany).

4.4.4. Swarming assay

Swarm agar plates were made using M8 medium supplemented with 0.2%
glucose, 0.5% casamino acid, 1 mM MgSO4 and solidified with 0.5 % Bacto agar.
Bacterial culture with OD600 between 0.4 to 0.6 was inoculated as 3 μl aliquots. Swarm
agar plates were incubated at 37 °C for 12 h and then incubated for an additional 12 h at
rt. For each set of the experiment, all the swarm plates were poured from the same batch
of agar and allowed to dry for 1 h before inoculation of bacteria.

4.4.5. Resazurin cell viability assay

On multi-array pegs, biofilms were grown for 24 h without and with 0.3 µg/mL
tobramycin to form control and tobramycin -promoted biofilms, respectively. The
medium was replaced with fresh medium supplemented with 50 µg/mL tobramycin, and
without or with 40 µM SFβM & 40 µM 2-ABI and cultured for the times indicated. The
biofilms were sonicated (15 min at 30 kHz). Resazurin was added to the sonicated
culture, followed by quantifying the fluorescence at 590 nm.
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Chapter 5 Selective Binding of Synthetic Disaccharide Derivatives to LecA Revealed
by Fluorescent Polarization*
5.1. Introduction
5.1.1. Background of Fluorescence polarization
Fluorescence polarization (FP) is a powerful method for probing protein-ligand
interactions, that involve the interaction of small fluorescent ligands with large
receptors.227-228 In 1926, Francis Perrin first described the theoretical basis of fluorescence
polarization.229 In the 1950s, Gregorio Weber extended Perrin’s theoretical work and
developed the first instrumentation to measure fluorescence polarization, and applied it to
study the interactions between dansyl chloride and bovine serum albumin.230-232 Since then,
the principles of fluorescence polarization have been applied extensively in assays to
enable high-throughput screening of small molecule libraries for the purposes of probe
development and drug discovery.233-236 Fluorescence polarization assay is based on the
rotational differences between the depolarization of the emitted light before and after the
interaction of molecules.237 A small fluorophore rotates in random directions, resulting in
rapid depolarization of light, while a larger complex molecule rotates slower and depolarize
light at a reduced rate. The difference in depolarization rate can be measured by
fluorescence spectrometer. Specifically, the small fluorophore in solution is first excited
by a linearly polarized light. The parallel and perpendicularly polarized components of the
fluorescence emissions are measured. If the fluorophore is unbound, the polarization

*

While I conducted all the experiments in this work, the idea of using fluorescent polarization to detect
LecA binding to out molecules is initiated by Pankaj Patil, and he contributed substantially to the design of
the experiments.
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anisotropy value remains at a relatively low level. If it is bound to a larger receptor, its
rotation is slowed, and the polarization anisotropy increases. In competition binding FP
assays, the presence of unlabeled ligands or small molecule inhibitors of the interaction
results in the displacement of the labeled fluorescent ligands, which increases the tumbling
motion of the free fluorescent ligands in the solution, and a decrease in FP value can be
detected.238 It has been widely used in numerous studies to measure the binding affinity
(IC50 or Kd measurement) of various receptors with their respective ligands.239-241
Fluorescence polarization assay is a homogeneous assay which can perform very quickly
since it does not require removal of unreacted reagents. Fluorescence polarization has
emerged as a technique which allows for high throughput and in situ detection of the
potency of a given competitive inhibitor.237, 242-243

5.1.2. Lectin protein of bacteria

Lectins are proteins that can bind specific carbohydrate structures which play
important roles in interactions and communication between bacterial, mammalian, plant or
fungi cells typically for recognition of glycan epitopes in multivalent carbohydrates and
glycoprotein receptors.244-245 Owing to carbohydrate binding specificity of lectins, they
have a huge impact on cell adhesion and host cell cytotoxicity, thus play a crucial role in
the pathogenic property of the parasite.246-248 In the case of P. aeruginosa, the bacteria
produce two lectins termed LecA (PA-IL) and LecB (PA-IIL).249-250 These lectins appear
to function in multistep adhesion events which involves proteolysis and elastolysis to be
cloned and sequenced as well as cytotoxins for respiratory epithelial cells.251-253 Galactose104

specific LecA is a tetrameric protein consisting of four 12.75-kDa subunits.249, 254 LecB is
about 12 ~13 kDa and exhibits a high specificity for fucose.250, 255 LecA and LecB have
both been shown to interact with the glycosphingolipid antigens, which is a huge factor for
the infectivity and pathogenicity of P. aeruginosa.256-257 The crystal structures of both
lectins show homotetrameric assemblies and calcium ions mediating the recognition of
their carbohydrate ligands.257-259 LecA has an intermediate affinity for its monovalent dgalactose-derived ligands in the Kd = 50–100 μM range and Phenyl -d-galactosides and
derivatives at approximately 10 μM.259-260 Recent studies revealed the affinities for LecA
in the nanomolar range based on divalent galactoside compounds.260-261 Here, we reveal the
selective binding of maltose and cellobiose derivatives to the bacterial LecA by a
fluorescence polarization-based assay.

5.1.3. The aim of the chapter
In this chapter, we designed and synthesized fluorescent-tag labeled ligand, βGalaryl-Dansyl, for LecA protein. We examined the ligand-receptor binding between βGalaryl-Dansyl and LecA by a fluorescence polarization-based assay and evaluated potential
ligands for LecA by competitive fluorescence polarization assay.

5.2. Results and discussion

5.2.1. Design of fluorescent-tag labeled ligand for LecA protein
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The fluorescent polarization has been developed and used to detect binding between
LecA and two phenyl-linked reporter ligands by Alexander Titz and coworkers.259 In their
work, they synthesize two fluorescent molecules (See Figure 5.1).

(Kd = 8.1 ± 2.1 μM)

(Kd = 19.2 ± 4.8 μM)

Figure 5.1 Structures of fluorophore-tagged phenyl glycosides for LecA ligands. The
listed dissociation constants are published in the literature.259

We design an efficient one-step synthesis of a fluorescently labeled ligand that
would also bind to LecA. This molecule will be used to establish a fluorescence
polarization assay with LecA. We explore this new structure because of the efficiency of
the synthesis (72 % yield). The ligand βGal-aryl-Dansyl is a D-Galactose-based probe
tethered with a dansyl group as the fluorescent part.
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Scheme 5.1 New Fluorescent Ligand Molecule, βGal-aryl-Dansyl, for LecA – Efficient
One-Step Synthesis

5.2.2. βGal-aryl-Dansyl binds to LecA with a Kd of 10.7 ±0.8 μM, based on by
fluorescence polarization

To evaluate the binding of βGal-aryl-Dansyl to LecA, a direct titration with
increased amounts of LecA was performed along with increased amounts of BSA as a
negative control. The ligand showed a dose-dependent increase in fluorescence
polarization with increasing concentration of LecA, while did not show any significant
effect on BSA (Figure 5.2). Kd value was obtained from a four-parameter fitting procedure
to the dose-dependent increase in fluorescence polarization by using Origin software. The
fitting equation is y = A1 + (A2-A1)/(1 + 10^((LOGx0-x)*p)), and A1 and A2 correspond
to bottom and top asymptotes, p is the hill slope and LOGx0 is the center value when
y=(A1+A1)/2. The model showed the fitted curve equation is: y=(0.12213-0.07179)/(1 +
10^((10.17-x)*0.052)), and the R2=0.97. The calculated Kd of the binding of βGal-arylDansyl to LecA is 10.17 ± 1.71 μM based on the direct binding curve derived from
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fluorescence polarization assay, which is consistent with the reported Kd values of phenylβ-galactoside derived ligands (Kd = 7.4 μM and 8.1 μM) in the low μM range.18
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Figure 5.2 Direct Titration of βGal-aryl-Dansyl (200 nM) with Increasing [LecA]
Revealed Kd of 10.17 ±1.71μM. Dissociation constants were obtained from a fourparameter fitting procedure to the dose-dependent increase in fluorescence polarization.
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5.2.3. The half maximal inhibitory concentrations (IC50) of synthetic molecules against
βGal-aryl-Dansyl are between 10-20 µM

The half maximal inhibitory concentration (IC50) of our synthetic molecules against
βGal-aryl-Dansyl were determined by competitive binding assay using FP. The basic
principle of the assay is shown in the Figure 5.3.A. Basically, in a competition binding FP
assays, the presence of unlabeled ligands or small molecule inhibitors of the interaction
results in the displacement of the labeled fluorescent ligands, which increases the tumbling
motion of the free fluorescent ligands in the solution, and a decrease in FP value can be
detected. The results revealed that IC50 of SFβM and SFβC are both at ~15 μM, and DβM
has an IC50 of ~19 μM. However, SFEG4OH and rhamnolipids did not show any binding
ability toward LecA (Figure 5.3.B).
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Figure 5.3 Competitive binding assay principle for monitoring LecA-ligand interaction
using fluorescence polarization (A). Fluorescent polarization reading of solutions of
LecA (final concentration: 20 µM) and βGal-aryl-Dansyl (200 nM) in 0.1M Tris-HCl pH
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7.5 and 6 μM CaCl2 with serial dilutions (0.1 μM to 100 μM) of test compounds, SFβM,
SFβC, DβM and SFEG4OH (B). IC50 was obtained from a four-parameter variable slope
model.

5.3. Conclusion
To conclude, we have used fluorescent polarization assay to show a fluorophorederivatized disaccharide can bind to LecA. We also showed that our potent molecules can
displace this fluorophore disaccharide from LecA, causing a decrease in fluorescence
polarization. Together these results in chapter 6 suggest that SFβM is a chimeric ligand
that binds to two different targets, LecA101-102, and pili,262 and also explains why two
distinct processes (biofilm formation and swarming) are inhibited by the same molecule.

5.4. Materials and Methods
5.4.1. Synthesis of βGal-aryl-Dansyl

4-Aminophenyl β-D-galactopyranoside(0.12 g, 1.2 mmol) in anhydrous DMF (2
mL) was added to Et3N (0.53 g, 0.53 mmol) in anhydrous DMF (5mL) at 0 ºC. To this
solution was added dansyl chloride (0.41 g, 1.5 mmol). After stirring at 0 ºC for 2 hr, the
mixture was concentrated, and the residue obtained was subjected to the purification by
column chromatography to yield a yellow solid product (0.44 g, 72 %). 1H NMR
(400MHz, CDCl3): δ 8.47 (d, 1 H, dansyl), 8.24 (d, 1 H, dansyl), 8.20 (d, 1 H, dansyl),
7.65-7.69 (m, 2 H, dansyl), 7.39 (d, 1 H, dansyl), , 6.92–6.81 (m, 4H, ArH), 4.75 (d, J =
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7.7 Hz, 1H), 4.37 (s, 2H, CH̲2NHR), 3.69 (d, J = 3.1 Hz, 1H), 3.58–3.46 (m, 5H), 2.84 (s,
6H,-CH3).

5.4.2. Direct binding of fluorescent ligands to LecA

The fluorescent ligands were dissolved in DMSO to a final concentration of 3 mg
mL−1. 2 mg LecA was dissolved in 1 mL of 0.1M Tris-HCl pH 7.5 and 6 μM CaCl2. A
serial dilution of LecA samples was prepared. The solution of one fluorescent ligand was
added to a final concentration (final concentrations of βGal-aryl-Dansyl: 200 nM). After
incubation for 1 h at r.t., fluorescence polarization was determined using Edinburgh
FLS9801 Spectrometer. During measurement, the samples were illuminated with vertically
polarized light at 330 nm (for βGal-aryl-Dansyl), and vertical and horizontal fluorescence
components were measured, and the fluorescence polarization values were calculated
subsequently.

5.4.3. Competitive binding assays

Typically, to a solution of LecA (final concentration: 20 µM) and fluorescent
ligand (final concentrations of βGal-aryl-Dansyl: 200 nM; FITC-EG12-SF: 20 nM) in
0.1M Tris-HCl pH 7.5 and 6 μM CaCl2, serial dilutions (0.1 μM to 100 μM) of test
compounds (SFβM, SFβC, DβM, SFEG4OH) were added. After the addition of the
reagents, the samples were incubated for 4–6 h at r.t. fluorescence polarization was
determined using Edinburgh FLS9801 Spectrometer. During measurement, the samples
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were illuminated with vertically polarized light at 330 nm (for βGal-aryl-Dansyl) and 490
nm (for FITC tagged fluorophore), and vertical and horizontal fluorescence components
were measured, and the fluorescence polarization values were calculated subsequently.

1

H NMR spectra
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Chapter 6 Pili-mediated Signaling Hypothesis and Validation.
6.1. Introduction
6.1.1. The attempt of using Pili as the vaccine target

Gram-negative bacterial surfaces have type IV pili, which can evoke the host
immune response and are potential drug and vaccine targets.263 Type IV pili are the
assembly of pilin subunits, which generates a polymeric “machinery” that can mediate
various cellular functions, including cell signaling, surface motility, microcolony, and
biofilm formation, host-cell adhesion.264-265 It has been reported that for many Gramnegative pathogens, disruption of pilus assembly can result in severely reduced
virulence.266-268 The Pseudomonas aeruginosa PAK pilin D-region is undergoing active
investigation as a vaccine target because anti-D-region antibodies could potentially block
the binding of a broad range of P. aeruginosa strains to the host-cell receptors.269
However, despite high numbers of patients who may develop P. aeruginosa infections
and the threat of antibiotic treatment failure due to bacterial resistance, there is
surprisingly no P. aeruginosa vaccine currently available on the market, although many
attempts have been made in the past, most of the published studies are preclinical, some
describe results from phases I and II studies and only two vaccines have made it phase III
studies in CF patients.270-271

6.1.2. Exploring bulky aliphatic chain of disaccharide derivatives for controlling
bacterial multicellular activities
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Based on the results from previous lab members in Luk’s group, among different
DSD, saturated farnesol disaccharide compound, like SFβM, has the highest anti-biofilm
ability.98-99 This observation leads us to explore even bulkier tail group to be attached on
disaccharide, which might increase anti-biofilm ability even more. A well-defined
binding pocket can bury the recognized ligands and exclude other molecules. The
conformation of the binding pocket might match well for the bulky tail compounds.
Furthermore, bulky tail DSD is relatively more difficult to assemble than non-bulky tail
DSD, because bulky hydrophobic tail DSD is more difficult to satisfy the
molecular packing requirements for forming a micelle than the non-bulky tail DSD. Since
bulky tail DSD is hard to form a micelle, it is more likely to move around in a free
molecule form. Hence, it has a higher chance to bind to the binding pocket (Figure 6.1).

Figure 6.1 Representation of the hypothesis that bulky hydrophobic tail surfactant is more
difficult to satisfy the molecular packing requirements for forming a micelle than the
non-bulky tail surfactant.

Cholestanol is a neutral lipid that plays an essential role in the maintenance of the
integrity of biologic membranes and serves as a precursor in the synthesis of many
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endocrine mediators.272 Recent clinical has demonstrated a possible linkage of
cholestanol to prostatic cancer and benign prostatic hyperplasia.273-275 Shinji and his
coworker have found that chemically synthesized sugar-cholestanol compounds showed
strong inhibiting activity against the proliferation of colorectal and gastric cancer cells.276
In recent work, chemically synthesized sugar-cholestanols were demonstrated to possess
potential multi-target anticancer activity against human esophageal cell lines because
they induced apoptotic cell death of esophageal cancer cells.277 Based on the past study
led by Gauri and Nischal in Luk group, a bulky aliphatic chain of disaccharide
derivatives, like SFβM, have the high anti-adhesion, and anti-biofilm formation and
dispersion activity.98, 149 We believe that bulky aliphatic chain that may cause higher
potency than saturated farnesol at enabling disaccharide derivatives on controlling
bacterial activity. We also speculate that inducing rigidity, multi-ring structures help limit
conformation space, which might further increase the potency for disaccharide
derivatives on controlling bacterial activity.

6.1.3. Covalent Ligation Strategy for Searching Pili Binding Sites

Covalent ligation has emerged as a valuable tool for the development of modified
proteins and the study of binding activities since the techniques that allows covalent
ligation have been developed over the last few decades.278-280 The complementary use of
both genetic and chemical methods has provided a large toolbox that allows us to
immobilize, cross-link or tag proteins or even alter protein properties.281 Covalent
ligation is highly specific and appending various probes to these ligands is synthetically
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straightforward and often does not reduce binding affinity for the protein targets since
nature also uses a covalent modification of proteins to modulate their function which
originated from millions of years of evolution, have adapted their structure for covalent
binding to proteins.282-283 The most straightforward method to covalently attach a small
molecule to a protein sequence is to use a binding interaction. For example, Nolan and
coworkers explored a fluorescein–SLF0 conjugate which was used to label several
FKBP12(F36V) fusion proteins in NIH3T3 and COS-7.284 Farinas and Verkman used
antibody tags fused to localization signal sequences to target various hapten– fluorophore
conjugates to specific subcellular compartments in live cells.285 One approach is to
engineer a mildly reactive functional group on the ligand molecule such that the ligand
does not lose its binding activity to its receptor protein, and upon binding, the mildly
reactive functional group will react covalently with a specific amino acid on the active
binding site of the receptor. A few such mildly reactive functional groups are known to
carry this binding enabled covalent conjugation. Chen and coworkers have surveyed a
range of affinity probes for protein labeling.286 Our initial design matches with their
finding that epoxy has great potential for protein modification yield and efficiency.
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Figure 6.2 Schematic Representation Covalent Ligation upon Binding between Ligand
and Receptor

6.1.4. Transmission electron microscopy of Surface Destructed Bacteria

The development of the transmission electron microscope (TEM), has increased
the resolution limit over one thousand times greater than the conventional light
microscope, which helped revolutionize many aspects of microbiology.287 In general, a
TEM system includes a fine electron beam, created by a high-voltage, electric currentheated tungsten filament, focused by magnetic lenses. The electron beam passes through
an ultrathin plastic section, which impedes the beam in proportion to their respective
degrees of electron density. The differential transmission of the electrons creates an
image that is captured on a fluorescent screen. The first functional transmission electron
microscope was developed in the early 1930s by Ruska who constructed an electron
microscope with three magnetic lenses, condenser, objective, and projector.288 After
scientists fully developed new methods for preparation and new procedures for fixation,
embedding, sectioning, and staining,289-293 TEM has been used as a strong research tool in
microbiology for high-resolution structural studies of bacteria and their appendages.294
TEM technique also allowed significant advances in the understanding of infection
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mechanisms, antibiotic tolerance, and biofilm geochemistry.295-297 TEM has the
advantage over scanning electron microscope (SEM), since a drastic preparation protocol
of SEM sample preparation may eliminate appendages.298 The TEM technique is widely
used to study the morphology of bacterial cells and their surface structures, such as
flagella and pili.299-302

6.1.5. Membrane Protein Study

Understanding of the properties of membranes is vital in many aspects of biology
since membrane plays important roles in the functioning of cells such as organizing the
shape of the organelles and the cells, the transport of ions, metabolites, and proteins
across plasma membranes, and RNA transport across nuclear membrane.303-305 Recently,
the complete genome sequencing estimated the transmembrane proteins represent over 30
% of total proteins.306-307 To understand how membrane proteins work and to generate
drugs that target specific sites within the protein, it is important to purify the protein to
fully characterize it. However, membrane proteins are difficult to purify for the following
reasons. First, most membrane proteins are present at low levels; and second, they are
embedded in the lipid bilayer and require detergents to become soluble in aqueous
systems.308 Large proteins whose molecular weight is above 250 kDa can be easily
separated as their individual subunits using simple centrifugation, while very small
proteins require special buffer systems in the second dimension to resolve proteins with
apparent masses less than 8 kDa.309 Hydrophobic proteins which include the key cellsurface proteins, many of which are assumed to play important roles in cell adhesion, cell

120

recognition, and cell differentiation require special systems such as extraction by using
urea, CHAPS, DTT, and alkaline buffers or sucrose density gradient centrifugation.309-312
Among them, alkaline extraction has gained widespread popularity as an easy and
efficient method for selectively stripping extrinsic proteins off membranes without
affecting the disposition of integral components.312

6.1.6. The aim of the chapter

In this chapter, we explored the effect of ChC3βM on these biological activities
by P. aeruginosa. In addition, to search the hypothetical receptor to gain insight into the
mechanism of ligand-receptor interactions, we also synthesized TEGβM and TGMEβM
to test their effect on biological activities by P. aeruginosa. To study the potential
interaction between our molecules and pili proteins, we designed and synthesized active
agents containing a functional group that can react with an amine group, which can
covalently and permanently attach to the receptor protein only when the physical ligandreceptor binding takes place. In addition, we also tested the effect of externally added pili
on the swarming motility of P. aeruginosa to support the mechanistic study of the pili as
the receptor (or one of the receptors) that will bind to rhamnolipids and our synthetic
agents, and upon binding, causing the bacterial activities. Furthermore, to study the effect
of our synthetic agents on the morphology of bacterial surfaces we have imaged bacterial
surfaces using a transmission electron microscope. In addition, we studied the membrane
protein composition using an alkaline buffer extraction method and then visualized by the
SDS-PAGE gel.
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6.2. Results and discussion
6.2.1. Cholestanol-sugar compound has activity at relatively low concentration but with
low potency

Quantification of PAO1 biofilm was done by crystal violet (CV) dye-based assay
after 24h of inoculation with and without maltose derivatives. We found that synthesized
ChC3βM exhibited biofilm inhibition activity against P. aeruginosa. At 10~20 µM
concentration, ChC3βM showed 60% biofilm inhibition. However, when the
concentration is higher, the biofilm inhibition rate decreased to 30%. Surprisingly, when
the concentration is reduced to nM level, ChC3βM still showed 20~30% biofilm
inhibition (Fig. 6.3).
If we assume that an optical density (OD) reading of 1 corresponds to 109 bacteria
per ml. This value is true for E. coli. Because E. coli and P. aeruginosa are similar in
shape and dimension, we adopted this value for our estimation. Thus, as OD=1
corresponds to 109 bacteria/ml, there are 2*107 bacteria in a well containing 200 µL
solution when OD=0.1. After 24 h incubation, the OD is approximately 1, which
corresponds to 2*108 bacteria in 200 µL. For the ChC3βM molecules, there are
1.2*1014 molecules in 200 µL of a 1 µM-solution. So even the concentration is reduced to
1 nM, the molecule number, 1.2*1011, is still about 1000-fold higher than bacteria
number (2*108). Thus, if we can reach IC50 at nM level, it would a significant
improvement for anti-biofilm drug development.
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Figure 6.3 Inhibition of biofilm by ChC3βM at different concentrations on PAO1
measured by CV dye assay. The compound showed biofilm inhibition activity at
relatively low concentration but with low potency.

6.2.2. Disaccharide oligo-ethylene glycol has an insignificant effect on bacteria

For synthesized DSD, TEGβM and TGMEβM, we tested their effect on swarming
motilities of PAO1 and rhlA on agar plates. According to the result of swarming assay,
TEGβM and TGMEβM have no effect on swarming motilities of both PAO1 and rhlA
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(Figure 6.4 and Figure 6.5). The steric and electronic structure of the aliphatic tail is
concluded to have great importance on the ability of these compounds to control bacterial
activities. In addition, C6OC5-β–Cellobiose, and C3OC8-β–Cellobiose have an
insignificant effect on the activities of P. aeruginosa (See chapter 3). Those results lead us
to hypothesize that there is a ligand-receptor mechanism involved with these signaling
molecules. The structure of the aliphatic side chain is important in the binding of these
compounds to the receptor, explaining why the introduction of a single ether linkage
obliterates the potency of our compounds since binding sites are often highly sensitive to
the molecular details of its ligands.

5 µM

15 µM

30 µM

85 µM

170 µM

No agent 85 µM DβM

rhlA
PAO1

Figure 6.4 Images of swarming motilities of PAO1 and rhlA on agar plates containing
different concentrations of TEGβM. The compound does not promote swarming of rhlA
or promote tendril formation in PAO1.
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Figure 6.5 Images of swarming motilities of PAO1 and rhlA on agar plates containing
different concentrations of TGMEβM. The compound does not promote swarming of
rhlA or promote tendril formation in PAO1.

6.2.3. The specific covalent ligating agent can bind to pilin, but not other proteins

PA1244 is a wild-type clinically isolated strain of Pseudomonas aeruginosa,
which is hyper-piliated.313 P. aeruginosa strain 1244N3 is a mutant of PA1244 that is
unable to produce pilin due to an inactivated rpoN gene.314 When inserted with plasmid
pPAC46, PA1244N3 could produce glycosylated pilin. Plasmid pPAC46 contains the
strain 1244 pilA and pilO genes under the control of a tac promoter. We successfully
purified a large amount of pili proteins using a P. aeruginosa PA1244N3/pPAC46 strain.
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Based on the preliminary results of MALDI-MS experiment, we have confirmed that pili
can be covalently modified by our agent available of covalent ligation, while other
proteins, like BSA and lysozyme, were not covalently modified by the same agent.
(Figure 6.6) In addition, among SF(EG)n-epoxy (n=3, 4, 5), SF(EG)4-epoxy has the
highest yield for covalent ligation with Pili protein (Figure 6.7).

Figure 6.6 SDS-PAGE gel image of purified pili protein and the MALDI-MS results.
Expressed Pili Protein from PA1244N3(pPAC46) Matches the Reported Mass of
16,307±25 (ref: James G. Smedley, Erica Jewell, Jennifer Roguskie, Joseph Horzempa,
Andrew Syboldt, Donna Beer Stolz, and Peter Castric,* Influence of pilin glycosylation
on Pseudomonas aeruginosa 1244 pilus function[J]. Infection and immunity, 2005,
73(12): 7922-7931.)
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Figure 6.7 MALDI-MS Result Indicates Pili is Covalently Modified by SF(EG)4-epoxy
(MW=459) in PBS (pH 8.2). Among SF(EG)n-epoxy (n=3, 4, 5), SF(EG)4-epoxy has the
highest yield for covalent ligation with Pili protein.

6.2.4. Supporting evidence of ligand-receptor binding between DSD and pili protein by
swarming assay

To support that pili could be the receptor that binds to rhamnolipids, and our
synthetic agents, we conducted an experiment where pili protein was applied on the
surface of the soft agar gel used for observing the swarming motility of wild-type P.
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aeruginosa, PAO1. If swarming is initiated by ligand-receptor binding between
rhamnolipids (or our molecules) and pili protein on the bacterium surfaces, then the
presence of pili proteins on the agar gel (outside the bacteria) will sequester the natural
molecules (rhamnolipids) secreted by the bacteria, and thus inhibit the bacteria’s
swarming motility. If bacterial swarming is a physical effect, the presence of pili protein
will unlikely not reduce the swarming motilities. Controls of other proteins (BSA) were
used to observe any nonspecific effect due to the presence of proteins on the gel. The
results indicate that pili protein inhibits swarming motility of PAO1, while BSA does not
inhibit the swarming motility of PAO1. (See Figure 6.8)

PAO1

Control

1.0 mg/mL Pili
(half surface)

0.5 mg/mL
BSA

0.5 mg/mL Pili

Figure 6.8 Pili protein inhibits swarming motility of PAO1 while BSA does not. After the
agar was cooled to r. t. and solidified, 1 mL of the corresponding solution was evenly
spread on the surface and dried for 1 h. Then 3 µL of the PAO1 culture (OD = 0.4 - 0.6)
was spotted on the center. Pictures were taken after the plates were put in 37 ℃
incubators for 12 h and then 22℃ for another 12 h.
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Previous lab member Gauri in Luk lab has examined the effect of a class of
synthetic analogs of rhamnolipids at controlling (promoting and inhibiting) the swarming
motility of a non-rhamnolipid-producing strain – rhlA – of P. aeruginosa. When the
swarming gel was supplemented with 85 uM DβM, the non-swarming PA strain rhlA will
swarm on the agar gel plate. Here we tested the effect of added pili protein on Swarming
Motility of rhlA in the Presence of 85 µM DβM. The results showed that the externally
added pili protein significantly reduced the swarm area of rhlA in the presence of 85 µM
DβM (Figure 6.9). In contrast, externally added BSA protein did not show any significant
inhibition on the swarming motility of rhlA in the presence of 85 µM DβM (Figure 6.9).
Those results support our proposed mechanism of ligand-receptor binding between
rhamnolipids (or our molecules) and pili protein.
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Figure 6.9 Pili protein inhibits swarming motility of rhlA in the presence of 85 µM DβM
while BSA does not. Predetermined concentrations of agents were added when preparing
the swarming agar plates. After the agar was cooled to r. t. and solidified, 1 mL of the
corresponding solution was evenly spread on the surface and dried for 1 h. Then 3 µL of
the rhlA culture (OD = 0.4 - 0.6) was spotted on the center. Pictures were taken after the
plates were put in 37 ℃ incubators for 12 h and then 22℃ for another 12 h.

However, there is another possibility that the externally added pili can act as a pili
inhibitor which can inhibit swarming motility by pili-pili interaction. To rule out such an
alternative mechanism of inhibition effect, we proposed another experiment to confirm
whether ligand-Pili interaction or pili-pili interaction is dominating in the inhibition effect
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of externally added pili protein (Figure 6.10). Predetermined concentrations of SFβM
were added in the swarming agar plates. Then 1 mL of 1.0 mg/mL of pili solutions were
spread on the agar plate and dried for 1 h. Controls of other proteins (BSA) were used to
observe any nonspecific effect due to the presence of proteins on the gel. PAO1 bacteria
were inoculated on the agar plates followed by 12 h incubation under 37 C and then
another 12 h under r.t. At 15 µM, SFβM inhibits swarming motility of PAO1. However,
under the same condition plus the externally added pili, the swarming inhibition effect of
SFβM was neutralized and the swarming pattern showed up again. Although the
swarming area of the re-promoted PAO1 is not as pronounced as the no agent control of
PAO1 swarming, the swarming re-promotion effect is still evident (Figure 6.11). The
results confirmed that pili protein inhibits swarming motility of PAO1 by ligand-Pili
interaction instead of pili-pili interaction.

Figure 6.10 Mechanism hypothesis: ligand-pili interaction or pili-pili interaction?
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Figure 6.11 Add swarm-inhibitor (SFβM) with pili in gel cause re-promotion of
swarming motility of PAO1. Predetermined concentrations of agents were added when
preparing the swarming agar plates. After the agar was cooled to r. t. and solidified, 1 mL
of the corresponding solution was evenly spread on the surface and dried for 1 h. Then 3
µL of the PAO1 culture (OD = 0.4 - 0.6) was spotted on the center. Pictures were taken
after the plates were put in 37 ℃ incubators for 12 h and then 22℃ for another 12 h.
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6.2.5. Bulky DSDs Like SRβM and rhamnolipids Modulate PA14 Swarming while other
potent agents that can control PAO1 and rhlA swarming have weak effects

PA14 always exhibit tendril formation when they swarm on a soft agar gel,
whereas PAO1 swarm evenly outward radially, resulting in a circle pattern. There are
currently no reported chemicals that control the swarming of PA14. However, we did
find that natural product rhamnolipids inhibit the swarming of PA14 starting at around 60
µM (Figure 6.12). Surprisingly, the potent agents that can modulate the swarming
motilities of PAO1, like DβM and BPDeβM, did not show any control of the swarming
motility of PA14. However, SRβM modulated the swarming motility of PA14. For this
molecule, swarming motility of PA14 was inhibited at relatively low concentration, 10
µM, but reactivated again as the concentration was increased. The swarming motility
reached a second maximum at 60 µM and then started to decrease again. A second
inhibition was observed at 170 µM. These results indicate that while pili structures vary
between different mutants and different strains. Such an oscillation effect of chemicals on
biological activities was described by Eberhard150 and coworkers for quorum sensing
molecules for Photobacterium fischeri. This oscillation in swarming pattern activity due
to the difference in chemical concentration is symbolic of an oscillatory response by the
bacteria to the chemical stimuli.151
Oscillations are ubiquitous in nature and occur in physical, chemical and
biological systems that are periodically repeating variations of some measure or quantity
about a central value or between two or more different states.151 At the cellular level, an
oscillating system consists of three parts: the oscillator, which generates the oscillatory
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output; the input pathways that regulates the oscillator in response to external or internal
signals; and output pathways that couple information about the state of the oscillator to
downstream targets in order to generate the oscillatory output.151 There are two types of
bacterial oscillators: Temporal oscillators which incorporate the periodic accumulation or
activity of a protein to drive temporal cycles such as the cell and circadian cycles,315 and
spatial oscillator which incorporate the periodic variation in the localization of a protein
to define subcellular positions such as the site of cell division316-317 and the localization of
DNA.318 However, the mechanisms of how these oscillators are designed and function
are still unclear.
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Figure 6.12 Images of P. aeruginosa PA14 strain inoculated on the M8 swarm agar
(0.5 % agar) plates with and without 85 µM of DSDS. Pictures were taken 24 h after the
inoculation of bacteria on the plates.
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6.2.6. Synthetic agents can destruct the bacterial surface of PAO1 and PA14

To observe the effects of our molecules on the bacterial surfaces by using TEM,
we cultured PAO1 with 20 µM of SFβM, and PA14 with 85 µM of SRβM and 170 µM of
rhamnolipids (a mixture of 3:1 di- and mono-rhamnolipids) in LB media to an optical
density about 0.4 to 0.5. We choose these polar hydrocarbons and concentrations because
these conditions inhibited the swarming motilities of PAO1 and PA14. The bacterial
culture solutions were directly placed on the copper grids for TEM, rinsed and then
stained with uranyl acetate. Figure 6.13 showed that intact bacteria of PAO1 and PA14
with some appendages readily visible for PAO1. In presence of 20 µM SFβM for PAO1,
a drastic effect was observed on the surfaces of the bacteria. Debris was released from the
bacteria, with some debris still attached to the bacteria. Similar phenomena were
observed for PA14. With 85 µM SRβM, some debris was seen; and with 170 µM
rhamnolipids, a considerable amount of debris was seen at the two polar ends of the
PA14 strain. We note that at these conditions, the bacteria were not dead, but their
pathogenic activities were grossly altered.
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Figure 6.13 Transmission electron microscopy of PAO1, PA14, and Mucoid PA strain
with and without treatment with their active agents in 4-h culture (OD=0.5). The samples
were stained with 0.5% (wt/vol) uranyl acetate.
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Figure 6.14 Hypothesis of Ligand Binding Causing Pili Assembly and Engine in
Membrane to Disassemble

In addition, to support the observation that our molecules disrupted the bacterial
surfaces using TEM, we also examined the membrane protein composition using an
alkaline buffer extraction method and then visualized by the SDS-PAGE gel. The result
showed alkaline buffer extracted a sample of PAO1 treated with 45 µM SFβM had a
significant decrease in protein expression at ~15 kDa than no agent control sample which
indicates the disrupted protein is most likely to be pili protein since the molecular weight
of pili protein is ~15-16 kDa region (Figure 6.15). As for the cause of the increase in the
protein expression at ~34 kDa and ~55 kDa range is not clear. However, the possible
surface protein that has a molecular weight of 34~55 kDa can be Putative pili assembly
chaperone, Type IV pili twitching motility protein PilT, Phosphate-binding protein PstS
or Pili assembly chaperone (see Table 6.1). These results support the hypothesis that our
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molecules target the pili assemblies of the bacteria, and because of the control of
bioactivities, induced a wide range of bacterial signaling events.

Figure 6.15 SDS-PAGE gel image of alkaline buffer extracted bacterial surface protein
composition. Samples were prepared from PAO1 bacteria cultures grown with and
without agents and purified by alkaline buffer extraction.
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Table 6.1 List of 9 possible surface proteins at 30-50 kDa range in Pseudomonas
aeruginosa species (source; http://www.uniprot.org/uniprot/)

6.2.7. The synthetic agent can inhibit twitching motilities of P. aeruginosa in solution

In order to have direct observation of the effect of our molecules on the motilities
of bacteria at the level of an individual bacterium, we observe the motility of individual
bacterium of P. aeruginosa that express fluorescent proteins PAO1-EGFP under a
confocal microscope. We discovered that without the presence of our agents, in every
second, there is about 7% of bacteria will either move in or out of the focal plane of the
fluorescence due to swimming or twitching motilities. However, in the presence of SFβM
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(10 µM, 6.1 µg/mL) and over the duration of 1 second, the entire bacteria population is
not motile (Figure 6.16). This inhibition of bacterial solution-based twitching and
swimming motility further supports that our agents bind to pili, and perhaps also flagella,
and inhibit the dynamic of these appendages (extension and retraction for pili, and
rotation for flagella).

Figure 6.16 One-second time lapse of confocal fluorescence of PAO1-EGFP (OD= 0.3 to
0.4) with and without 10 µM SFβM in the media. The images at the 3rd and 4th second
were shown; the red circles indicate changes: bacteria that move bacteria into (appear)
and out of (disappear) the focal plane due to the twitching motion. The numbers of
“appear” and “disappear” bacteria are plotted for the bacterial sample without the agent
(empty triangles) and sample with 10 µM SFβM (filled circle).
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6.2.8. Attempts at making a fluorescently tagged pilin ligand

In order to obtain more direct evidence of ligand-receptor binding between our
molecules and pili appendage on bacterial surfaces, we designed ligand molecules with
covalently attached fluorescent tags, and explore their use of direct observation of
fluorescently active surface appendages on bacteria, and of fluorescent polarization.

In the past, such direct observations were obtained by modifying the amino acid
of pilin monomers with cysteine amino acid, which will covalent attach to a fluorescent
label. This approach enables a “live” observation of the dynamics and biology of the pili
appendages. Another approach involves direct binding of a fluorescently active antibody
to pilin of the pili appendage and makes a direct observation on the microscope.

Because our indirect evidence suggests that our molecules bind to pili assembly
on bacterial surfaces, we explore the following design of fluorescently labeled ligand
molecules. Synthesis schemes for two fluorescent tagged DSDs, Pyrenyl-C11-βM (18)
and UmDeβM (24) were shown in Scheme 6.1. However, the separation of Pyrenyl-C11βM encountered the major difficulty that most of the compound was stuck with the resin
in the last deacylation step. According to the 1H NMR spectra of the Pyrenyl-C11-βM
(18), most of the -OH peaks were disappeared from the final product. UmDeβM (24) has
been successfully synthesized and the swarming assay was tested for this molecule.
Unfortunately, UmDeβM did not show any modulating effect on the swarming motility
of both PAO1 and rhlA strains of Pseudomonas aeruginosa (Figure 6.17).
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Scheme 6.1. Synthesis schemes for fluorescent-tagged DSDs
143

Figure 6.17 Images of swarming motilities of PAO1 and rhlA on agar plates containing
different concentrations of UmDeβM. The compound does not promote swarming of rhlA
or promote tendril formation in PAO1.

6.3. Conclusions

Molecules capable of covalent ligation were designed and synthesized, and their
multiple biological effects on P. aeruginosa bacteria were tested. The results show that
one of our synthetic molecules SF(EG)4-epoxy is nontoxic and no biofilm Inhibition
effect but capable of controlling bacterial swarming of PAO1. Pili protein was
successfully purified by using P. aeruginosa bacteria strain that can overproduce pili
proteins. To study the potential interaction between our synthetic molecules and pilin
proteins, mixing experiment were done by using the pili protein and several other
proteins (Lysozyme and BSA) with the synthetic molecule SF(EG)4-epoxy, which is
capable of covalent ligation. The results indicate that SF(EG)4-epoxy can covalently
attach to the receptor protein ONLY when the ligand-receptor take place. Swarming
motility of P. aeruginosa was tested with protein solutions (Pili protein and BSA) spread
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on agar gel. Pili protein inhibits swarming of PAO1 and also inhibits swarming of rhlA in
the presence of 85 µM DβM (this condition was supposed to promote swarming of rhlA).
While BSA does not inhibit swarming of PAO1, and rhlA in the presence of 85 µM
DβM. The results further indicate that pili are the receptor (or one of the receptors) that
will bind to rhamnolipids and our synthetic agents, and upon binding, causing the
bacterial activities. We also imaged damaged pili on bacterial surfaces using TEM. These
results indicate that pili appendage is the target of SFβM.

6.4. Materials and Methods

6.4.1. Stock solutions of generic surfactants and maltose derivatives
A stock solution of all the agents was prepared in autoclaved water, sterilized by
filtering through a 0.2 μm 16 syringe filter, and stored at -20 °C in sealed vials. An
appropriate amount of sterile water was added to controls in all assays to eliminate the
solvent effect.

6.4.2. Swarming assay
Swarm agar plates were made using M8 medium supplemented with 0.2%
glucose, 0.5% casamino acid, 1 mM MgSO4 and solidified with 0.5 % Bacto agar.
Bacterial culture with OD600 between 0.4 to 0.6 was inoculated as 3 μl aliquots. Swarm
agar plates were incubated at 37 °C for 12 h and then incubated for an additional 12 h at
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rt. For each set of the experiment all the swarm plates were poured from the same batch
of agar and allowed to dry for 1 h before inoculation of bacteria.

6.4.3. Crystal violet dye-based biofilm inhibition assay
Inhibitory effect of all the maltose hydrocarbons on P. aeruginosa biofilm
formation was determined by crystal violet dye-based biofilm inhibition assays. An
overnight culture of wild-type P. aeruginosa (PAO1) was subcultured to an OD600 of
0.01 into the 95/5 M9+/LB medium (The places where only LB medium has been used is
indicated in the figure caption). 200 μL of the subculture was aliquoted into the wells of
96 well polystyrene microtiter plate when it reached the OD600 of 0.1. Predetermined
concentrations of the test compounds were then added to the respective wells containing
subculture. Sample plates were wrapped in GLAD Press n’ Seal® followed by incubation
under stationary conditions for 24 h at 37 °C. After incubation, the media was discarded,
and the plates were washed with water and dried for 1 h at 37 °C. The sample plates were
stained with 200 μL of 0.1% aqueous solution of crystal violet (CV) and followed by
incubation at ambient temperature for 20 min. The CV stain was then discarded, and the
plates were washed with water. The remaining biofilm adhered stain was re-solubilized
with 200 μL of 30 % acetic acid. After the stain was dissolved (15 minutes), 100 μL of
the solubilized CV was transferred from each well into the corresponding wells of a new
polystyrene microtiter dish. Biofilm inhibition was quantified by measuring the OD600
of each well in which a negative control lane wherein no biofilm was formed served as a
background and was subtracted out. The percent inhibition was calculated by the
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comparison of the OD600 for biofilm grown in the absence of compound (control) versus
biofilm grown in the presence of compound under identical conditions.

6.4.4. Solution-based bacteria twitching assay.
An overnight culture of bacteria was subcultured to an OD600 of 0.01 into the LB
medium containing predetermined concentrations of the test compounds. 10 µL of the
subculture was transferred onto a glass slide when it reached the OD600 of 0.3-0.4.
Twitching motilities were visualized using a Zeiss LSM 710 Confocal Laser Scanning
Microscope (Carl Zeiss, Jena, Germany). A 488 nm laser line was used to visualize
twitching motilities of PAO1-EGFP strain.

6.4.5. Ligand-Pili receptor conjugation reactions.
300 µL of SF(EG)4-epoxy (50 equiv., 1.6 mg) from a stock solution of 11.5 mM
in deionized water (18.2 MΩ.cm) was added to a 1 mL solution containing 1 mg/mL
lysozyme (14307 Da) or pili protein (15648 Da) or bovine serum albumin protein
(~66000 Da) in PBS pH 8.2 (reaction buffer). The reaction mixture was shaken at 250
rpm for 24 h at ambient temperature in a shaker-incubator. These samples were sent out
for MALDI-MS at Rutgers University (http://cabm-ms.cabm.rutgers.edu/) to characterize
the potential covalent modification of the proteins.

6.4.6. Transmission electron microscopy.
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A small number of bacteria from the edge or the center of the colony on the
swarming plate was picked using a sterile toothpick and dispersed in PBS buffer by
gently touching the toothpick to the liquid for 5 s. A droplet of the bacterial suspension
was placed onto a copper TEM grid. After waiting for 15 min, the remaining solution was
wicked away using a piece of filter paper. The samples were then rinsed with 2 ml of 2
mM HEPES buffer (pH 6.8) followed by a rinse with 1 ml of MilliQ water. The samples
were then stained by placing a drop of 0.5% (wt/vol) uranyl acetate onto the samples and
removing the excess by wicking with filter paper after 3 to 5 min. TEM pictures were
imaged using a 120 kV field FEI T12 Spirit TEM Equipped with a LaB6 filament, single
and double tilt holder, an SIS Megaview III CCD camera, and a STEM dark field and
bright field detector, along with analysis and imaging software.

6.4.7. Alkaline buffer extraction.

Set up overnight cultures for P. aeruginosa from frozen stocks. Conditions: 10 ml
LB broth in 50 ml Falcon tube at 37 °C shaking at 200 rpm. Next day, set up fresh cultures
from the overnight cultures in new LB broth using a 1:100 ratio dilution, and grow at 37
°C shaking at 200 rpm until the exponential growth phase (0.4 - 0.6 OD600). Centrifuge the
culture at 3,000 x g for 5 min at 4 °C. Discard the supernatant and gently resuspend the
pellet in 10 ml of PBS. Centrifuge at 3,000 x g for 10 min at 4 °C, discard supernatant and
resuspend pellet in 3 ml 20 mM Tris pH 7.4. Centrifuge at 3,000 x g for 10 min at 4 °C ,
discard the supernatant and resuspend the pellet in 0.1 M Na2CO3. Keep on ice for 30 min.
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Use 1 mL syringe pass cells suspension through a >22-gauge needle 10 times (or other
gentle cells lyse methods). Centrifuge 3,000 x g for 20 min at 4 °C to remove unlysed
cells. Resuspend the pellet in 0.1 M Na2CO3, re-extract as above and pool the
supernatants. Combine the supernatants and neutralize by adding HCl drop by drop. The
supernatant is transferred to a fresh tube and centrifuged at 30,000 x g for 40 minutes at 4
°C. Take off the supernatant and the left pellets are ready for running SDS-PAGE.

6.4.8. Synthetic procedures

Scheme 6.2. Synthesis scheme for ChC3βM
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β-cholestanone (2)
Lit. ref. for characterization data: Org. Lett. 2013, 15, 992-995.
To a suspension of pyridinium chlorochromate (2.21 g, 10.29 mmol) and silica gel
(2.21 g) in 10 mL dichloromethane, β-cholestanol (1) (2.0 g, 5.14 mmol) dissolved in 10
mL dichloromethane was added. The resulting black/orange solution was stirred at room
temperature for 4 h. The reaction mixture was then filtered through a bed of silica gel. The
residue was washed with dichloromethane. The filtrate was concentrated to afford βcholestanone (1.91 g, 96%) as a white solid. White powder; TLC: Rf = 0.36 (10% ethyl
acetate/90% hexanes); 1H NMR (CDCl3, 400 MHz): δ 2.37-2.30 (m, 3H), 2.26-0.85 (m,
40H), 0.68 (s, 3H).

(3)
A solution of 2 (1.5 g, 3.88 mmol) and 1, 3-butanediol (1.0 g, 11.1 mmol) was
refluxed overnight under toluene (25 ml) in the presence of pyridinium p-toluenesulfonate
(50 mg). Molecular sieve (type 3A) was added to remove water formed during the reaction.
Concentration and silica gel chromatography (elution with 3% ethyl acetate in hexane)
afforded 3 (1.5 g, 3.31 mmol, 85%) as a white solid. TLC: Rf = 0.60 (5% ethyl acetate/95%
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hexanes); 1H NMR (CDCl3, 400 MHz): δ 3.82-3.74(m, 2H), 3.61(m, 1H), 3.50(m, 1H),
2.26-0.85 (m, 47H), 0.68 (s, 3H).

(4a)
Add 3 (1.2 g, 2.6 mmol) in 8 mL anhydrous ether to a previously prepared
solution of LiAIH(0.30 g, 7.5 mmol) and A1C13 (0.35 g, 2.5 mmol) in 8 mL anhydrous
ether. The reduction was allowed to proceed at room temperature for 12 h. Then 15%
aqueous KOH was added dropwise to decompose the complex and form a colorless
precipitate which was readily removed by filtration. Concentration and silica gel
chromatography (elution with 3% ethyl acetate in hexane) afforded 4a (0.62 g, 1.3 mmol,
50%). TLC: Rf = 0.70 (15% ethyl acetate/85% hexanes); 1H NMR (CDCl3, 400 MHz): δ
3.50-3.70(m, 4H), 3.38-3.30(m, 1H), 2.26-0.55 (m, 50H).

(4b)
Add 3 (1.2 g, 2.6 mmol) in 8 mL anhydrous ether to a previously prepared
solution of LiAIH(0.30 g, 7.5 mmol) and A1C13 (0.35 g, 2.5 mmol) in 8 mL anhydrous
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ether. The reduction was allowed to proceed at room temperature for 12 h. Then 15%
aqueous KOH was added dropwise to decompose the complex and form a colorless
precipitate which was readily removed by filtration. Concentration and silica gel
chromatography (elution with 3% ethyl acetate in hexane) afforded 4b (0.30 g, 1.3 mmol,
24%). TLC: Rf = 0.65 (15% ethyl acetate/85% hexanes); 1H NMR (CDCl3, 400 MHz): δ
3.64-3.58(m, 3H), 3.45-3.37(m, 1H), 3.24-3.15(m, 1H), 2.26-0.50 (m, 50H).

(6a)

Maltose (0.2 g, 0.5mmol), AcBr (~0.6mL, 8 mmol), and AcOH (5mL) were
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The
crude aceto-bromo sugars were immediately used in next step without any further
purification.

Crude aceto-bromo sugars were the dissolved in MeCN (10mL) and 4a (1.0mmol, 2
equivalents) were added along with acid 2-equivalents of a Lewis catalyst FeCl3. The
reaction mixture was stirred vigorously for about ~45-60 mins at rt. After stirring at rt, aq
KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The organic phase
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was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3 (5%, 25mL) and
twice with H2O (2×25mL). The crude product was then purified by column
chromatography using gradient elution (100 % hexane to 35 % ethyl acetate in hexane).
Concentration and silica gel chromatography afforded 6a (0. 22g, 0.2 mmol, 20%) TLC:
Rf = 0.45 (35% ethyl acetate/65% hexanes); 1H NMR (CDCl3, 400 MHz): δ 5.43-5.33 (m,
2H), 5.29-5.26 (m, 1H), 5.09-5.02(m, 1H), 4.89-4.79 (m, 2H), 4.52 – 4.45 (m, 2H), 4.29 –
4.21 (m, 2H), 4.06-3.93 (m, 3H), 3.88 – 3.68 (m, 2H), 3.52 – 3.35 (m, 2H), 3.30-3.15(m,
2H) 2.15 – 2.01 (s, 7 × 3 H), 2.26-0.50 (m, 50H).

(6b)

Maltose (0.2 g, 0.5mmol), AcBr (~0.6mL, 8 mmol), and AcOH (5mL) were
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The
crude aceto-bromo sugars were immediately used in next step without any further
purification.
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Crude aceto-bromo sugars were the dissolved in MeCN (10mL) and 4a (1.0mmol, 2
equivalents) were added along with acid 2-equivalents of a Lewis catalyst FeCl3. The
reaction mixture was stirred vigorously for about ~45-60 mins at rt. After stirring at rt, aq
KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The organic phase
was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3 (5%, 25mL) and
twice with H2O (2×25mL). The crude product was then purified by column
chromatography using gradient elution (100 % hexane to 35 % ethyl acetate in hexane).
Concentration and silica gel chromatography afforded 6b (0. 37g, 0.35 mmol, 32%) TLC:
Rf = 0.40 (35% ethyl acetate/65% hexanes); 1H NMR (CDCl3, 400 MHz): δ 5.43-5.33
(m, 2H), 5.29-5.26 (m, 1H), 5.09-5.02(m, 1H), 4.89-4.79 (m, 2H), 4.52 – 4.45 (m, 2H),
4.29 – 4.21 (m, 2H), 4.06-3.93 (m, 3H), 3.88 – 3.68 (m, 2H), 3.55 – 3.32 (m, 3H), 3.323.17(m, 1H) 2.15 – 2.01 (s, 7 × 3 H), 2.26-0.50 (m, 50H).

(7a)
Zemplén deacetylation. For all acetylated sugar-derivatized hydrocarbon
molecules, the deprotection of alcoholic groups was achieved by Zemplén deacetylation
using MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5)
over H+ amberlite resins. The resins were filtered off and products dried under high
vacuum overnight. White solid, Yield: 7a (0.07 g, 88 %), 1H-NMR (CD3OD, 400 MHz):
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δ 5.17 (d, J = 3.6 Hz, 1H), 4.28 (d, J = 7.8 Hz, 1H), 3.92-3.78 (m, 4 H), 3.72 – 3.15 (m,
15H, overlapping with CD3OD), 2.26-0.50 (m, 50H).

Scheme 6.3. Synthesis scheme for TEGβM

(8)

Maltose (1.0 g, 2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~
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1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The
crude aceto-bromo sugars were immediately used in next step without any further
purification.

Crude aceto-bromo sugars were then dissolved in MeCN (10mL) and TEG
(5.6mmol, 2 equivalents) were added along with acid 2-equivalents of a Lewis catalyst
FeCl3. The reaction mixture was stirred vigorously for about ~45-60 mins at rt. After
stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The
organic phase was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3
(5%, 25mL) and twice with H2O (2×25mL). The crude product was then purified by
column chromatography using gradient elution (100 % hexane to 50 % ethyl acetate in
hexane). Concentration and silica gel chromatography afforded 8 (0.6 g, 0.8 mmol, 29%)
TLC: Rf = 0.55 (50% ethyl acetate/50% hexanes); 1H NMR (CDCl3, 400 MHz): δ 5.625.55(m, 1H), 5.38-5.30(m, 2H), 5.08-4.95(m, 1H), 4.86-4.80(m, 1H), 4.70-4.65(m, 1H),
4.52-4.45(m, 1H), 4.30-4.17(m, 3H), 4.12-3.98(m, 3H), 3.93-3.88(m, 1H), 2.15 – 2.01 (s,
7 × 3 H).

(9)
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Zemplén deacetylation. For all acetylated sugar-derivatized hydrocarbon
molecules, the deprotection of alcoholic groups was achieved by Zemplén deacetylation
using MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5)
over H+ amberlite resins. The resins were filtered off and products dried under high
vacuum overnight. White solid. Yield: 9 (0.35 g, 85 %), 1H NMR (CDCl3, 400 MHz): δ
5.20-5.16 (m, 1H), 4.26-4.21 (m, 1H), 3.97-3.88 (m, 1H), 3.82-3.40 (m, 17H), 3.383.27(m, 2H),3.22-3.12 (m, 4H).

Scheme 6.4. Synthesis scheme for TGMEβM
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(10)

Maltose (1.0 g, 2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The
crude aceto-bromo sugars were immediately used in next step without any further
purification.

Crude aceto-bromo sugars were the dissolved in MeCN (10mL) and TGME
(5.6mmol, 2 equivalents) were added along with acid 2-equivalents of a Lewis catalyst
FeCl3. The reaction mixture was stirred vigorously for about ~45-60 mins at rt. After
stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The
organic phase was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3
(5%, 25mL) and twice with H2O (2×25mL). The crude product was then purified by
column chromatography using gradient elution (100 % hexane to 50 % ethyl acetate in
hexane). Concentration and silica gel chromatography afforded 10 (0.6 g, 0.8 mmol,
29%) TLC: Rf = 0.55 (50% ethyl acetate/50% hexanes); 1H NMR (CDCl3, 400 MHz): δ
5.62-5.40(m, 2H), 5.38-5.22(m, 1H), 5.08-4.95(m, 1H), 4.90-4.78(m, 2H), 4.65-4.60(m,
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1H), 4.52-4.45(m, 1H), 4.30-4.17(m, 2H), 3.93-3.85(m, 5H), 3.76-3.52(m, 11H), 3.38 (s,
3H), 2.15 – 2.01 (s, 7 × 3 H).

(11)

Zemplén deacetylation. For all acetylated sugar-derivatized hydrocarbon
molecules, the deprotection of alcoholic groups was achieved by Zemplén deacetylation
using MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5)
over H+ amberlite resins. The resins were filtered off and products dried under high
vacuum overnight. 1H-NMR (CD3OD, 400 MHz): δ 5.20-5.16 (m, 1H), 4.26-4.21 (m,
1H), 3.97-3.88 (m, 1H), 3.82-3.40 (m, 20H), 3.38 (s, 3H),3.36-3.24 (m, 3H).
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Scheme 6.5. Synthesis scheme for SRβM

(14)
Add 1 equivalent of retinol acetate and 10 equivalents of 10% Pd/C in EtOAc.
Hydrogenation is proceeded under 125 psi hydrogen. The reaction was filtered over
celite and washed with EtOAc to remove any excess product in the celite. Slowly add 1
equiv. LAH to a solution of saturated retinol acetate in THF(0.2M) at 0ºC. Allow to
warm to room temperature and stir for 16h. The reaction was filtered over celite and the
filtrate was concentrated to dryness without further purifications.
To an oven dried round bottom flask, disaccharide (maltose, cellobiose) (1.0 g,
2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were added and stirred at
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room temperature (25 ⁰C) for ~ 1 h. The reaction mixture was concentrated in vacuo at
35 ⁰C and then co-evaporated three times with PhMe (2×10 mL, anhydrous). After
removal of solvent, the flask was further heated in vacuo at 50 ⁰C for 15min to give a
foamy solid, aceto-bromo sugar. The crude aceto-bromo sugars were immediately used in
next step without any further purification. The crude aceto-bromo sugars were then
dissolved in MeCN (10mL) and saturated retinol (5.6mmol, 2 equivalents) were added
along with two equivalents of FeCl3 .The reaction mixture was stirred vigorously for
about ~45-60 mins at rt. After stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL)
were added under stirring. The organic phase was washed twice with aq KBr (10%,
2×25mL), once with aq NaHCO3 (5%, 25mL) and twice with H2O (2×25mL). The crude
product was then purified by column chromatography using gradient elution (100 %
hexane to 35 % ethyl acetate in hexane). Concentration and silica gel chromatography
afforded 14 (0. 37g, 0.35 mmol, 32%) TLC: Rf = 0.40 (35% ethyl acetate/65% hexanes);
1

H NMR (CDCl3, 400 MHz): δ 5.43-5.33 (m, 2H), 5.29-5.26 (m, 1H), 5.09-5.02(m, 1H),

4.89-4.79 (m, 2H), 4.52–4.45 (m, 2H), 4.29–4.21 (m, 2H), 4.06-3.93 (m, 3H), 3.88–3.68
(m, 2H), 3.55 – 3.32 (m, 3H), 3.32-3.17(m, 1H) 2.15-2.01 (s, 7 × 3 H), 1.52-0.83 (m, 37H
aliphatic chain).

(15)

161

The deprotection of acetyl groups was achieved by Zemplén deacetylation using
MeONa/MeOH (10 mM solution) conditions followed by neutralization (pH ~6.5) over
H+ amberlite resins. The resins were filtered off and products dried under high vacuum
overnight. 1H-NMR (CD3OD, 400 MHz): δ 5.17 (br, s, 1H), 4.27 (d, J = 9 Hz, 1H), 3.953.92 (m, 4H), 3.88-3.43 (m, 6H, overlap with CD3OD peak), 3.27-3.20 (m, 4H), 1.600.88 (m, 37H aliphatic chain).

(16)
1-(1-pyrenyl)-11-bromo-1-undecanone
In a 5 mL round bottom flask, 1.8 mL (24.8 mmol) of thionyl chloride was added
to 1.0 g (3.8 mmol) of 11-bromoundecanoic acid. The mixture was heated at 40°C for 4 h
and then stirred at room temperature for 12 h. After removal of the excess of thionyl
chloride by rotavap, the residual colorless oil was dissolved in 6 mL of dry CH2Cl2,
transferred in a two neck round bottom flask, and cooled to 0°C in an ice bath. Upon
addition of 0.72 g (3.6 mmol) of pyrene and 0.57 g (4.3 mmol) of AlCl3, the reaction was
stirred for 5 h at 0°C. The reaction mixture was then poured on an ice/water/Et2O
mixture. The organic layer was washed three times with water and dried over Mg2SO4.
After removal of solvent, purification of the crude product on silica gel, using
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hexane/Et2O (9:1) as eluent, yielded the intermediate product I as a yellow solid (98%).
1

H NMR (CDCl3, 400 MHz): 8.93 (d, 1H, Ar), 7.92-8.31 (m, 8H, Ar), 3.44 (t, 2H, CH2

ω), 3.22 (t, 2H, CH2 α), 1.94 (m, 2H, CH2 ω-1), 1.22-1.53 (m, 14H, aliphatic chain).

(17)

11-(1-pyrenyl)-1-bromoundecene was prepared according to a reported procedure.
Briefly, in a two-neck, round bottom flask fitted with a reflux condenser, 0.45 g (3.4
mmol) of AlCl3 dissolved in 5 mL of dry Et2O were added dropwise to a 1 M solution of
LiAlH4 in dry Et2O. Then, 0.5 g (1.1 mmol) of 16 dissolved in 10 mL of dry CH2Cl2 were
added dropwise to the mixture cooled to 0 °C in an ice bath, and the reaction mixture was
stirred at room temperature and monitored by TLC (hexane/Et2O 9:1) until disappearance
of 16 (~3 h). The reaction was quenched by the addition of 10 mL of Et2O and 10 mL of
water; the organic layer was washed several times with HCl 1 M and dried over Mg2SO4.
Removal of the solvent yielded a yellow solid (90%). 1H NMR (CDCl3, 400 MHz): 7.748.22 (m, 9H, Ar), 3.3 (m, 4H), 1.1-1.9 (m, 18H, aliphatic chain).
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(18)
A mixture of 17 (200mg, 0.56mmol) and NaHCO3 (320mg, 3.8mmol) in DMSO
(3.8mL) was heated to reflux for 1 h. Then saturated NaHCO3 solution and CH2Cl2 were
added at room temperature. The organic layer was extracted with saturated NaCl solution,
dried (MgSO4), and evaporated and the residue was purified by flash chromatography
(hexane/ EtOAc 3:1) to give 97 mg (59%) as a colorless solid. 1H NMR (CDCl3, 400
MHz): δ 9.77(t, 1H), 7.72-8.24 (m, 9H, Ar), 3.32(t, 2H), 2.41(t, 2H), 1.14-1.92 (m, 18H).

(19)
(Need repeat)

Maltose (1.0 g, 2.8mmol), AcBr (~3.6mL, 44.4mmol), and AcOH (19mL) were
added to an oven dried round bottom flask and stirred at room temperature (25 ⁰C) for ~
1 h. The reaction mixture was concentrated in vacuo at 35 ⁰C and then co-evaporated
three times with PhMe (2×10 mL, anhydrous). After removal of solvent, the flask was
further heated in vacuo at 50 ⁰C for 15min to give a foamy solid, aceto-bromo sugar. The
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crude aceto-bromo sugars were immediately used in next step without any further
purification.

Crude aceto-bromo sugars were then dissolved in MeCN (10mL) and 18
(5.6mmol, 2 equivalents) were added along with acid 2-equivalents of a Lewis catalyst
FeCl3. The reaction mixture was stirred vigorously for about ~45-60 mins at rt. After
stirring at rt, aq KBr (10%, 25mL) and then PhMe (60mL) were added under stirring. The
organic phase was washed twice with aq KBr (10%, 2×25mL), once with aq NaHCO3
(5%, 25mL) and twice with H2O (2×25mL). The crude product was then purified by
column chromatography using gradient elution (100 % hexane to 50 % ethyl acetate in
hexane). Concentration and silica gel chromatography afforded the acetylated product
(0.6 g, 0.8 mmol, 29%). The deprotection of acetyl groups was achieved by Zemplén
deacetylation using MeONa/MeOH (10 mM solution) conditions followed by
neutralization (pH ~6.5) over H+ amberlite resins. The resins were filtered off and
products dried under high vacuum overnight. 1H NMR (400 MHz, MeOD) showed the
product is not pure, need to synthesize this again.

1,10-Decanediol di-p-tosylate, TsOC10H20OTs (20)

165

In an overnight oven-dried round bottom flask, 1, 10-decanediol (1 g, 5.7 mmol)
and 4-toluenesulfonyl chloride (2.3 g, 12 mmol) were dissolved in dry dichloromethane
(60 ml) at 0 °C. Upon the addition of pyridine (0.94 g, 12 mmol) the reaction mixture
was allowed to stir vigorously under argon environment and warmed to room temperature
overnight. The reaction mixture was concentrated in vacuo. The reaction crude was
diluted with 1:1 H2O:CH2Cl2 (120 ml). The organic layer was washed with brine (3*30
ml) and dried over Na2SO4. Upon removal of solvents, 1,10-Decanediol di-p-tosylate was
afforded as a white solid (2.29 g, 4.8 mmol, 98%). TLC: Rf=0.48 (hexanes:ethyl acetate,
7:3). 1H NMR (CDCl3, 400 MHz): δ 7.79 (4H, d, J=8 Hz, -C2H4C2H4CS-), 7.34 (4H, d,
J=8 Hz, CH3CC2H4C2H4-), 4.00 (4H, t, J=6.8 Hz, TsOCH2CH2-), 2.45 (6H, s, -PhCH3),
1.62 (4H, p, J=6.8 Hz, TsOCH2CH2-), 1.2 (6H, s, b, Aliphatic), 1.18 (6H, s, b, Aliphatic).

UmOC10H20OTs (21)

In an overnight oven-dried round bottom flask, umbelliferone (0.162 g, 1 mmol)
was dissolved in dry MeCN (10 ml), and K2CO3 (0.140 g, 1 mmol) was added. The
reaction mixture was stirred at room temperature for 15 minutes, then treated with 1, 10decandiol ditosylate (1.01 g, 2.1 mmol). The reaction mixture was heated with an oil bath
to 65 ˚C and allowed to stir vigorously at for 12 h under Ar environment. After cooling,
the reaction mixture was concentrated, diluted with 1:1 CH2Cl2: H2O (20 ml). The
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organic layer was washed with brine, dried over MgSO4, and concentrated in vacuo. The
reaction crude was diluted with CH2Cl2, mixed with SiO2 (80%). Upon removal of the
solvent, the crude mixture was purified with flash chromatography (hexane: ethyl acetate,
3:1) to give Umbelliferone Decanol Tosylate Ether as a colorless oil (0.223g, 0.47 mmol,
47%). TLC: Rf=0.34 (hexanes:ethyl acetate, 7:3). 1H NMR (CDCl3, 400 MHz): δ 7.80
(2H, d, J=8.4 Hz, -C2H4C2H4CS-), 7.64 (1H, d, J=9.6 Hz, -CH=CHC-), 7.37 (2H, d,
J=8.4 Hz, CH3CC2H4C2H4-), 7.35 (1H, d, J=6.8 Hz, -CHCHC(OH)-), 6.84 (1H, dd,
J=8.8, 2.4 Hz, -CCHCH-), 6.81 (1H, d, J=2 Hz, -CCHC(OH)-), 6.25 (1H, d, J=9.6 Hz, OC(=O)CH=CHC-), 4.03 (2H, t, J=6.8 Hz, UmOCH2CH2-), 4.0 (2H, t, J=6.8 Hz,
TsOCH2CH2-), 2.46 (3H, s, -PhCH3), 1.81 (2H, p, J=6.8 Hz, Aliphatic), 1.65 (2H, p,
J=6.8 Hz, Aliphatic), 1.69 (2H, d, J=7.6 Hz), 1.45 (2H, p, J=6.8 Hz, Aliphatic), 1.2-1.4
(8H, m, Aliphatic).

UmDe Alcohol, UmOC10H20OH (22)

In a clean and dry round bottom flask, UmDe Tosylate (0.443 g, 0.937 mmol) was
dissolved in a stirring mixture of 0.5 M aq. NaOH (2 ml, 2 mmol) and MeCN (8 ml). The
reaction mixture was heated with an oil bath to 78 ˚C and allowed to stir vigorously at for
12 h. After cooling, the reaction mixture was quenched with 0.5 M HCl (2 ml, 2 mmol),
concentrated, then diluted with 1:1 CH2Cl2: H2O (20 ml). The organic layer was washed
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with brine, water, and dried over MgSO4, and concentrated in vacuo. Upon removal of
the solvent, the crude mixture was purified with flash chromatography (hexane: ethyl
acetate, 7:3) to give UmDe Alcohol as a white solid (26 mg, 0.082 mmol, 8.6%). TLC:
Rf=0.24 (hexanes:ethyl acetate, 7:3). 1H NMR (CDCl3, 400 MHz): δ 7.64 (1H, d, J=9.6
Hz, -CH=CHC-), 7.36 (1H, d, J=6.8 Hz, -CHCHC(OH)-), 6.84 (1H, dd, J=8.8, 2.4 Hz, CCHCH-), 6.81 (1H, d, J=2 Hz, -CCHC(OH)-), 6.25 (1H, d, J=9.6 Hz, OC(=O)CH=CHC-), 4.02 (2H, t, J=6.4 Hz, UmOCH2CH2-), 3.66 (2H, t, J=6.4 Hz,
HOCH2CH2-), 1.84 (2H, t, J=6.8 Hz, Aliphatic), 1.6-1.4 (10H, m, Aliphatic), 1.36 (8H, s,
Aliphatic).

Per-acetyl UmDeβM (23)
To an oven dried round bottom flask, maltose (0.072 g, 0.2 mmol) was dissolved
in AcOH (2 ml), then treated with AcBr (~0.30 mL, 4.0 mmol). The reaction mixture was
allowed to stir at room temperature (25 ⁰C) for ~ 1 h. The reaction mixture was
concentrated in vacuo at 35 ⁰C. After removal of solvent, the reaction crude was coevaporated with anhydrous toluene (2×3 mL) at 40 ⁰C to further remove residual acetic
acid to give aceto-bromo sugars as a foamy solid. The crude aceto-bromo maltose was
immediately used in next step without any further purification. The crude aceto-bromo
maltose (~0.2 mmol) was dissolved in MeCN (10mL) along with UmOC10H20OH (0.096
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g, 0.3 mmol). To this reaction mixture was added two FeCl3 (0.033 g, 0.4 mmol). The
reaction mixture was stirred vigorously for about 60 mins at rt. Then 10% aq. KBr (3 ml)
and toluene (5 ml) were added under stirring. The organic phase was subsequently
washed with 10% aq. KBr (2×3 ml), 5% aq NaHCO3 (5%, 3 ml), and H2O (2×3 ml).
Upon removal of solvent, the crude mixture was purified with flash chromatography
(hexane: ethyl acetate, 1:1) to give Per-acetyl UmDeβM as a white solid (19 mg, 0.020
mmol, 10%). TLC: Rf=0.29 (hexanes:ethyl acetate, 1:1). 1H NMR (CDCl3, 400 MHz): δ
7.64 (1H, d, J=9.6 Hz, -CH=CHC-), 7.37 (1H, d, J=8.4 Hz, -CHCHC(OH)-), 6.84 (1H,
dd, J=8.8, 2.4 Hz, -CCHCH-), 6.81 (1H, d, J=2 Hz, -CCHC(OH)-), 6.25 (1H, d, J=9.2
Hz, -OC(=O)CH=CHC-), 5.43-5.34 (2H, m, maltose), 5.26 (1H, t, J = 9.2 Hz, anomeric),
5.07 (1H, t, J = 9.6 Hz, anomeric), 4.89-4.80 (2H, m, maltose), 4.53-4.46 (2H, m,
maltose), 4.28-4.22 (2H, m, maltose), 4.07-3.96 (2H, m, UmOCH2CH2-), 4.07-3.96 (2H,
m, MOCH2CH2-), 4.07-3.96 (1H, m, -CHCH2OAc), 3.85 (1H, m, -CHCH2OAc), 3.67
(1H, m, -CHCH2OAc), 3.47 (1H, m, -CHCH2OAc), 2.15-2.01 (7 x 3H, s, CH3C(=O)O),1.81 (2H, t, J=7.6 Hz, Aliphatic), 1.47 (2, t, J=7.6 Hz, Aliphatic), 1.45-1.25 (16H, m,
Aliphatic).

UmDeβM (24)

169

To an oven dried round bottom flask, per-acetyl UmDeβM (30 mg, 32.02 mmol)
was dissolved in 10 mM CH3ONa/CH3OH (10 ml). The reaction was allowed to stirred
at room temperature under argon environment for 12 hours; then followed by
neutralization (pH ~6.5) over H+ amberlite resins. After the resins were filtered off, the
filtrate was concentrated in vacuo at 35 ⁰C to afford UmDeβM as a light-yellow solid (14
mg, 21.78 mmol, 66%). TLC: Rf=0.18 (methanol). 1H NMR (CD3OD, 400 MHz): δ 7.88
(1H, d, J=9.2 Hz, -CH=CHC-), 7.53 (1H, d, J=8.4 Hz, -CHCHC(OH)-), 6.92 (1H, dd,
J=8.8, 2.4 Hz, -CCHCH-), 6.89 (1H, d, J=2 Hz, -CCHC(OH)-), 6.24 (1H, d, J=9.2 Hz, OC(=O)CH=CHC-), 4.26 (1H, d, J = 9.2 Hz, anomeric), 3.90-3.83 (5H, m, maltose), 4.07
(2H, t, J=6.4 Hz, UmOCH2CH2-), 3.81 (1H, t, J = 6.4 Hz, anomeric), 3.80-3.65 (5H, m,
maltose), 3.61 (2H, J=9.6 Hz, MOCH2CH2-), 3.6-3.5 (2H, m, -CHCH2OH), 3.3-3.2 (2H,
m, -CHCH2OH), 1.81 (2H, t, J=7.2 Hz, Aliphatic), 1.62 (2H, t, J=7.6 Hz, Aliphatic), 1.50
(2H, m, Aliphatic), 1.35 (10H, bs, Aliphatic).

Scheme 6.6. Synthesis scheme for SF(EG)n-epoxy (n=3,4,5)

170

General procedure for the synthesis of SF(EG)nOH (n=3, 4, 5)
Saturated farnesol (1 equiv.) and triphenylphosphine (1.1 equiv.) were dissolved in DMF
under nitrogen atmosphere. Bromine was added drop by drop until the solution turned
orange in color and flask temperature was maintained below 55 ºC. Reaction was allowed
to stir at rt for additional 12 h. Reaction mixture was concentrated in vacuo and the
resulting product was purified over column chromatography (15% EtOAc/hexanes) to
afford the desired product SFBr. Then (EG)nOH (n=3, 4, 5) (2 equiv.) was dissolved in
dry DMF and cooled to 0 ºC for 5 min. To the reaction mixture was added NaH (60%
dispersion in mineral oil) (1 equiv.) at 0 °C and the reaction was further stirred for one
hour. SFBr (1 equiv.) was added and the mixture was stirred at rt overnight. Reaction
mixture was concentrated in vacuo and then dissolved in Et2O (15 mL). Organic layer
was washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was
filtered and concentrated in vacuo. The reaction mixture was purified by column
chromatography (40 % EtOAc/ Hexane) to afford SF(EG)nOH (n=3, 4, 5).

SF(EG)3-epoxy (25)
SF(EG)3OH (0.11 g, 0.30 mmol) was dissolved in 1 mL dry DMF and cooled to 0 ºC for
5 min. To the reaction mixture was added NaH (60% dispersion in mineral oil) (0.04 g,
0.33 mmol) at 0 °C and the reaction was further stirred for one hour. Epibromohydrin
(0.05 g, 0.33 mmol) was added and the mixture was stirred at rt overnight. Reaction
mixture was concentrated in vacuo and then dissolved in Et2O (5 mL). Organic layer was
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washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was filtered
and concentrated in vacuo. The reaction mixture was purified by column chromatography
(25 % EtOAc/ Hexane) to afford 25 (0.06 g, 47%). 1H NMR (400 MHz, CDCl3) δ 3.73
(dd, 1H), 3.70-3.63 (m, 9H), 3.60-3.53(m, 1H), 3.51-3.38(m, 3H), 3.21-3.12 (m, 1H),
2.84-2.77(m, 1H), 2.65-2.60 (m, 1H), 1.64-1.08 (m, 19H), 0.94-0.89 (m, 12H).

SF(EG)4-epoxy (26)
SF(EG)4OH (0.22 g, 0.60 mmol) was dissolved in 2 mL dry DMF and cooled to 0 ºC for
5 min. To the reaction mixture was added NaH (60% dispersion in mineral oil) (0.08 g,
0.66 mmol) at 0 °C and the reaction was further stirred for one hour. Epibromohydrin
(0.10 g, 0.66 mmol) was added and the mixture was stirred at rt overnight. Reaction
mixture was concentrated in vacuo and then dissolved in Et2O (10 mL). Organic layer
was washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was
filtered and concentrated in vacuo. The reaction mixture was purified by column
chromatography (40 % EtOAc/ Hexane) to afford 26 (0.13 g, 45%). 1H NMR (400 MHz,
CDCl3) δ 3.73 (dd, 1H), 3.70-3.63 (m, 13H), 3.60-3.53(m, 1H), 3.51-3.38(m, 3H), 3.213.12 (m, 1H), 2.84-2.77(m, 1H), 2.65-2.60 (m, 1H), 1.64-1.08 (m, 19H), 0.94-0.89 (m,
12H).
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SF(EG)5-epoxy (27)
SF(EG)5OH (0.17 g, 0.40 mmol) was dissolved in 1 mL dry DMF and cooled to 0 ºC for
5 min. To the reaction mixture was added NaH (60% dispersion in mineral oil) (0.05 g,
0.44 mmol) at 0 °C and the reaction was further stirred for one hour. Epibromohydrin
(0.07 g, 0.44 mmol) was added and the mixture was stirred at rt overnight. Reaction
mixture was concentrated in vacuo and then dissolved in Et2O (5 mL). Organic layer was
washed with water (10 mL x 3), brine and dried over Na2SO4. Organic phase was filtered
and concentrated in vacuo. The reaction mixture was purified by column chromatography
(25 % EtOAc/ Hexane) to afford 27 (0.06 g, 47%). 1H NMR (400 MHz, CDCl3) δ 3.73
(dd, 1H), 3.70-3.63 (m, 17H), 3.60-3.53(m, 1H), 3.51-3.38(m, 3H), 3.21-3.12 (m, 1H),
2.84-2.77(m, 1H), 2.65-2.60 (m, 1H), 1.64-1.08 (m, 19H), 0.94-0.89 (m, 12H).
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